MRI Characterization of Radiation Necrosis in an Animal Model: Time to Onset, Progression, and Therapeutic Response by Jiang, Xiaoyu
Washington University in St. Louis
Washington University Open Scholarship
All Theses and Dissertations (ETDs)
10-31-2013
MRI Characterization of Radiation Necrosis in an
Animal Model: Time to Onset, Progression, and
Therapeutic Response
Xiaoyu Jiang
Washington University in St. Louis
Follow this and additional works at: https://openscholarship.wustl.edu/etd
Part of the Chemistry Commons
This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has been accepted for inclusion in All
Theses and Dissertations (ETDs) by an authorized administrator of Washington University Open Scholarship. For more information, please contact
digital@wumail.wustl.edu.
Recommended Citation
Jiang, Xiaoyu, "MRI Characterization of Radiation Necrosis in an Animal Model: Time to Onset, Progression, and Therapeutic
Response" (2013). All Theses and Dissertations (ETDs). 1186.
https://openscholarship.wustl.edu/etd/1186
 
 
WASHINGTON UNIVERSITY IN ST. LOUIS 
Department of Chemistry 
 
Dissertation Examination Committee: 
Joseph J.H. Ackerman, Chair 
Joel R. Garbow 
Dennis E. Hallahan 
Joshua Maurer 
Demetrios Sarantites 
Joseph R. Simpson 
John-Stephen Taylor 
 
MRI Characterization of Radiation Necrosis in an Animal Model: Time to Onset, Progression, 
and Therapeutic Response 
By 
Xiaoyu Jiang 
 
A dissertation presented to the 
 Graduate School of Arts and Sciences  
of Washington University in 
partial fulfillment of the  
requirements for the degree  
of Doctor of Philosophy 
 
December 2013 
St. Louis, Missouri 
ii 
 
Table of Contents 
ACKNOWLEDGEMENT ............................................................................................................................................... 4 
ABSTRACT ..................................................................................................................................................................... 6 
CHAPTER 1 INTRODUCTION ..................................................................................................................................... 1 
1.1 MOTIVATION ..................................................................................................................................................... 1 
1.2 STATE OF RESEARCH ........................................................................................................................................ 1 
1.2.1 Radiation necrosis following radiation treatment of central nervous system ............................................ 1 
1.2.2 Magnetic Resonance Imaging (MRI) in characterizing radiation necrosis ............................................. 11 
1.2.3 Animal model of radiation necrosis .......................................................................................................... 24 
1.2.4 Gamma-Knife irradiation ......................................................................................................................... 28 
1.3 AIMS AND OUTLINE ........................................................................................................................................ 29 
REFERENCES ............................................................................................................................................................... 31 
CHAPTER  2 DEVELOPMENT AND OPTIMIZATION OF A MOUSE MODEL OF RADIATION NECROSIS .. 41 
DECLARATION ............................................................................................................................................................. 41 
INTRODUCTION ........................................................................................................................................................... 42 
MATERIALS AND METHODS ........................................................................................................................................ 45 
RESULTS ...................................................................................................................................................................... 49 
MRI detects radiation necrosis as image hyperintensity in contrast-enhanced T1-weighted images ................. 49 
Radiation dose schedules affect the onset and progression of radiation necrosis ............................................... 49 
Neuropathological Grading System in the Murine Model of Radiation Necrosis. ............................................... 49 
Histological scores for radiation necrosis correlate with MR-derived necrotic volumes .................................... 51 
DISCUSSION ................................................................................................................................................................ 52 
CONCLUSION ............................................................................................................................................................... 53 
FIGURES ...................................................................................................................................................................... 54 
REFERENCES ............................................................................................................................................................... 60 
CHAPTER 3 ANTI-VEGF ANTIBODIES MITIGATE THE DEVELOPMENT OF RADIATION NECROSIS ...... 63 
DECLARATION ............................................................................................................................................................. 63 
INTRODUCTION ........................................................................................................................................................... 64 
MATERIALS AND METHODS ........................................................................................................................................ 66 
RESULTS ...................................................................................................................................................................... 70 
MRI detects radiation necrosis as image hyperintensity in T2-weighted images ................................................. 70 
Necrosis volumes can be measured quantitatively from MR images .................................................................... 70 
Anti-VEGF antibodies slow the progression of radiation necrosis in irradiated brain tissue ............................. 71 
Histology reveals that anti-VEGF antibodies mitigate radiation necrosis in irradiated brain tissue ................. 72 
DISCUSSION ................................................................................................................................................................ 73 
CONCLUSION ............................................................................................................................................................... 75 
ACKNOWLEDGMENTS ................................................................................................................................................. 75 
COMPLEMENTARY DATA .............................................................................................................................................. 76 
DCE MR imaging ................................................................................................................................................... 76 
Anti-VEGF antibodies decrease the vasculature permeability in the necrotic region ......................................... 76 
FIGURES ...................................................................................................................................................................... 77 
REFERENCES ............................................................................................................................................................... 85 
CHAPTER 4 A GSK-3β INHIBITOR PROTECTS AGAINST RADIATION NECROSIS IN MOUSE BRAIN...... 88 
DECLARATION ............................................................................................................................................................. 88 
INTRODUCTION ........................................................................................................................................................... 89 
MATERIALS AND METHODS ........................................................................................................................................ 91 
RESULTS ...................................................................................................................................................................... 95 
MRI detects radiation necrosis as image hyperintensity in T1-weighted images ................................................. 95 
iii 
 
Necrosis volumes can be measured quantitatively from MR images .................................................................... 95 
GSK-3β inhibitor slows the progression of radiation necrosis in brain tissue .................................................... 96 
Histology reveals that GSK-3β inhibitor protects against radiation necrosis in irradiated brain tissue ............ 96 
GSK-3β inhibitor does not affect the therapeutic efficacy of radiation on tumor tissue ..................................... 96 
DISCUSSION ................................................................................................................................................................ 98 
CONCLUSION ............................................................................................................................................................... 99 
ACKNOWLEDGMENTS ................................................................................................................................................. 99 
FIGURES .................................................................................................................................................................... 100 
REFERENCES ............................................................................................................................................................. 108 
CHAPTER 5 CHARACTERIZING RADIATION NECROSIS USING QBOLD .................................................... 111 
5.1 INTRODUCTION ................................................................................................................................................... 111 
5.2 METHODOLOGY .................................................................................................................................................. 112 
5.2.1 qBOLD theory ............................................................................................................................................. 112 
5.2.2 MRI pulse sequence .................................................................................................................................... 116 
5.2.3 Auto shimming ............................................................................................................................................ 118 
5.2.4 Numerical simulation.................................................................................................................................. 118 
5.2.5 Data processing .......................................................................................................................................... 119 
5.3 RESULTS .............................................................................................................................................................. 121 
Numerical simulation optimizes the qBOLD imaging parameters ..................................................................... 121 
Auto shimming reduces the macroscopic magnetic field inhomogeneities ......................................................... 127 
VSF method reduces signal loss due to macroscopic magnetic field inhomogeneities ...................................... 132 
Resulting OEF and dCBV maps .......................................................................................................................... 134 
5.4 DISCUSSION......................................................................................................................................................... 136 
5.5 CONCLUSION ....................................................................................................................................................... 137 
REFERENCES ............................................................................................................................................................. 139 
CHAPTER 6 SUMMARY AND FUTURE RESEARCH ........................................................................................... 141 
6.1 SUMMARY .................................................................................................................................................... 141 
6.2 FUTURE RESEARCH ............................................................................................................................................. 142 
Optimize the dosing schedule of B20-4.1.1 in the treatment of RN .................................................................... 142 
Verify the mechanism of anti-VEGF antibody in the treatment of RN ................................................................ 142 
Determine the efficacy of other commercialized GSK-3β inhibitors as neuroprotectant................................... 143 
Improve qBOLD in the brain of small animal ..................................................................................................... 143 
Develop an animal model of tumor and necrosis ................................................................................................ 144 
REFERENCES ............................................................................................................................................................. 145 
 
iv 
 
Acknowledgement 
 
I thank my two advisors, Prof. Joseph J. H. Ackerman and Prof. Joel R. Garbow, for their 
guidance and support during this thesis research and graduate study at Washington University. 
They provided expert direction, a state-of-art research environment and the ability to work with 
distinguished collaborators. Thanks to Prof. Dmitriy A. Yablonskiy and Dr. Alexander L. 
Sukstanskii, for their help in qBOLD study and data analysis. Thanks to John A. Engelbach for 
his help in animal operations. My thanks are extended to those members, both current and past, 
of the Biomedical Magnetic Resonance Laboratory at Washington University in St. Louis: 
Xiaoqi Wang, Donghan Yang, Chong Duan, Jeff R. Anderson, Kathleen E. Chaffee, Carlos 
Perez-Torres, Scott Beeman.  
I also thank my collaborators: Dr. Liya Yuan, Jeremy Cates, Dr. Feng Gao, Dr. Robert E. 
Drzymala, Dr. Keith M. Rich and Dr. Dinesh Thotala. 
This thesis research has been supported by NIH grants R01 CA155365 (JRG), R01 CA174966 
(DEH), and R01 CA140220-01 (DEH), and funding from the Alvin J. Siteman Cancer Center, an 
NCI-comprehensive cancer center, P30 CA091842, the Barnes-Jewish Hospital Foundation 
Cancer Frontier Fund, and Elekta Instruments AB (Stockholm, Sweden). I gratefully 
acknowledge Genentech (South San Francisco, CA) for donation of anti-VEGF antibody B20-
4.1.1. 
I thank my Dissertation Advisory and Examination Committee members, Prof. Joseph J.H. 
Ackerman, Prof. Joel R. Garbow, Prof. Joshua Maurer, Prof. John-Stephen Taylor, Prof. 
Demetrios Sarantites, Prof. Joseph R. Simpson, and Prof. Dennis E. Hallahan. 
Lastly a lot of thanks to my parents for their continued support, love, and encouragement 
v 
 
throughout my graduate study. Many thanks to my wife for her fabulous cooking skills and my 
20-month old daughter for her lovely smile.  
 
 
 
Xiaoyu Jiang 
Washington University in St. Louis 
August 2013  
 
 
 
 
 
 
 
 
 
vi 
 
ABSTRACT OF THE DISSERTATION 
MRI characterization of radiation necrosis in an animal model: time to onset, progression, and 
therapeutic response 
By 
Xiaoyu Jiang 
Doctor of Philosophy in Chemistry 
Washington University in St. Louis, 2013 
Professor Joseph Ackerman, Chair 
 
Radiation necrosis is a severe, but late occurring type of injury to normal tissue, within and 
surrounding a radiation treatment field, which can lead to significant complications for 
neurooncology patients. Radiation necrosis is difficult to distinguish from recurrent tumor by 
either neurologic examination or clinical imaging protocols. Concerns for the development of 
radiation necrosis often limit therapeutic radiation doses. Current treatment options for radiation 
necrosis are limited. The development of solutions to these clinical challenges has been 
hampered by an appropriate animal model of radiation necrosis.  
With a novel mouse model of radiation necrosis developed in our lab employing a Gamma Knife, 
which enables high-dose, fractionated, hemispherical irradiation in the mouse brain, the 
objectives were to i) optimise radiation dosing schemes (total dose, fractionation) for this 
Gamma-Knife mouse-model of radiation necrosis; ii) determine the efficacy of bevacizumab 
(Avastin) and its murine analog B20-4.1.1, both vascular endothelial growth factor (VEGF) 
inhibitors, as mitigators of radiation necrosis in mice; iii) validate the neuroprotective effect of 
SB 415286, an inhibitor of glycogen synthase kinase 3β (GSK-3β ), in mouse brain following 
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high-dose radiation treatment; and iv) identify and validate the quantitative blood oxygen level 
dependent (qBOLD) method as an imaging marker of radiation necrosis. 
For these purposes, a series of experiments were performed, including monitoring the onset and 
progression of radiation necrosis in mice receiving different dose schedules, comparing the 
development of radiation necrosis in irradiated mice with or without treatments, and mapping the 
irradiated and non-irradiated mouse brains using qBOLD method.  
It was found that i) radiation dose schedules affect the onset and progression of radiation necrosis; 
ii) anti-VEGF antibodies slow the progression of radiation necrosis in irradiated brain tissue; iii) 
SB 415286 protects against and mitigates radiation necrosis in irradiated brain tissue; and iv) a 
high SNR (400 at least) is required to decouple oxygen extraction fraction (OEF) and 
deoxyhemoglombin cerebral blood volume (dCBV) in mouse brain using qBOLD method. In 
qBOLD, the voxel spread function (VSF) reduces the effect of macroscopic magnetic field 
inhomogeneities. However, with current shimming methods, imaging parameters, and post-
processing algorithms, the resulting OEF and dCBV maps in the mouse brain are not reliable.  
These results demonstrated that the development of radiation necrosis in this Gamma Knife 
mouse model can be characterized by both anatomic MR imaging and histology. Both anti-
VEGF therapy and GSK-3β inhibition could be potential therapeutic managements for radiation 
necrosis, but further studies are needed to optimize dosing schemes and treatment periods and 
elucidate mechanisms of action. Characterizing radiation necrosis in mouse brain using qBOLD 
remains a challenge due to the imperfect correction for macro magnetic field inhomogeneities.  
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Chapter 1 Introduction 
 
 
1.1 Motivation 
Radiotherapy is the most efficient treatment for curing or mitigating malignant tumors with 
approximately 50% of all cancer patients receiving radiation therapy during their course of 
illness. However, despite the use of sophisticated, fractionated, high-dose radiation or 
radiosurgery methods designed to spare normal tissue, about 20% of patients experience 
radiation necrosis (RN) three or more months following therapy. Further, the presence of RN 
complicates/masks the identification/diagnosis of recurrent tumor. To date, no single imaging 
modality has been shown to reliably distinguish RN from recurrent tumor and no standard 
therapy has been shown to protect against, or effectively mitigate, RN [1]. Identification of 
necrosis and development of therapeutics to treat necrosis are challenging clinical problems. The 
development of solutions to these critical clinical challenges has been hampered by the lack of a 
well-developed, small-animal model of RN. A Gamma-Knife mouse-model of RN, in concert 
with MRI monitoring, provides a powerful and translatable platform to i) elucidate the critical 
determinants governing the onset and progression of injury; ii) evaluate 
neuroprotective/mitigative agents; and iii) define the MR signatures distinguishing necrosis from 
recurrent tumor.  
  
1.2 State of Research 
1.2.1 Radiation necrosis following radiation treatment of central nervous system 
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Radiation is a key component in the treatment of both benign and malignant central nervous 
system (CNS) tumors, including gliomas, metastases, meningiomas, schwanomas, pituitary 
adenomas, and other less common neoplasms. Multiple radiation-treatment schemes have been 
developed to treat various neoplasms in the brain. These treatment protocols utilize a variety of 
different fractionation and conformational schemes designed to deliver focused radiation to 
regions in the brain to maximize control of tumor growth and minimize deleterious effects on 
normal brain tissue. Outcomes of these clinical protocols may be complicated by radiation-
induced injury on non-neoplastic tissue. Based on the time of clinical expression, radiation-
induced injury is described as ‘acute’, ‘early delayed’ or ‘late delayed injury’ [2]. Acute injury, 
occurring in days to weeks after irradiation, is rare with current radiation therapy techniques. 
Early delayed injury occurs 1–6 months post-irradiation and can involve transient demyelination 
with somnolence. Although both of these early injuries can produce severe reactions, they are 
normally reversible and resolve spontaneously. In contrast, late delayed injury, characterized 
histopathologically by vascular abnormalities, demyelization, and ultimately white matter 
necrosis, is usually observed more than 6 months post irradiation. These delayed effects from 
radiation are generally considered as irreversible and progressive. They may produce cerebral 
edema and necrosis of normal brain parenchyma, resulting in untoward neurologic effects that 
are difficult to differentiate from recurrent tumor growth. 
Radiation necrosis (RN), a delayed radiation injury that can occur after radiation treatment of the 
CNS, can develop between 3 months and 10 years after radiotherapy, with most cases occurring 
in the first two years. Necrosis following radiation is not uncommon, occurring in 3-24% of 
patients receiving focal irradiation. Several studies have suggested a direct relationship between 
radiation-induced injury and different radiation doses, fractionation schemes, and adjuvant 
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treatments. Total radiation dose was determined to be the most important risk factor. In cases 
where fractionated therapy is used, larger fractional doses are more likely to cause subsequent 
RN. The incidence of RN may be threefold higher with concurrent chemotherapy [3]. Other risk 
factors include lesion volume and location, old age, and vascular risk factors, including diabetes. 
1.2.1.1 Pathobiology of radiation necrosis 
The biology of RN is poorly understood. Two mechanisms have been proposed to explain 
cerebral RN: the glial injury hypothesis and the vascular injury hypothesis [4].  
The glial injury hypothesis 
The glial injury hypothesis initially focused on oligodendrocytes, which are required for the 
formation of myelin sheaths. Oligodendrocyte type-2 astrocyte (O-2A) progenitor cells, the key 
cells for generating mature oligodendrocytes, lose their reproductive capacity after whole brain 
irradiation in the rat, ultimately leading to a failure to replace oligodendrocytes. But the 
hypothesis that oligodendrocytes depletion results in demyelination and white matter necrosis, is 
questionable. It has been reported that no changes in the number of myelinated axons, the 
thickness of myelin sheaths, and the cross-sectional area of myelinated axons have been 
measured in cognitively impaired rats 12 months post irradiation [7]. In addition, although the 
kinetics of oligodendrocyte depletion is consistent with an early transient demyelination, it is 
inconsistent with the late onset of white matter necrosis. Thus, the relationship between radiation 
damage to oligodendrocytes and late radiation-induced injury is still unclear. 
Astrocytes, constituting approximately 50% of the total glial cell population in the brain, are 
recognized as a heterogeneous class of cells that perform diverse functions, including 
biochemical support of endothelial cells that form the blood-brain barrier (BBB), provision of 
nutrients to the nervous tissue, maintenance of extracellular ion balance, and a role in the repair 
4 
 
and scarring process of the brain and spinal cord following traumatic injuries. In response to 
radiation injury, astrocytes undergo proliferation and exhibit hypertrophic nuclei/cell bodies. 
These reactive astrocytes produce vascular endothelial growth factor (VEGF) and hypoxia-
inducible factor 1α (HIF-1α), which also potentiates the upregulation of VEGF [5]. As a result of 
VEGF upregulation, BBB dysfunction becomes worse and increases cerebral edema and hypoxia 
[6]. Although, their exact role in the overall pathogenesis of late delayed radiation-induced brain 
injury is still unclear, astrocytes likely contribute by interacting with both vascular and other 
parenchymal elements in the brain.  
Microglia, representing 10-15% of the total glial cell population within the brain, act as the first 
and main form of active immune defense in the CNS. After injury, microglia become activated, a 
process characterized by rounding of the cell body, retraction of cell processes, proliferation, and 
increased production of reactive oxygen species, cytokines, and chemokines that mediate 
neuroinflammation [7]. Radiation-induced microglia activation plays an important role in the 
formation of RN. An increased percentage of activated microglia has been detected in the 
irradiated rat brain before the expression of late radiation-induced brain injury [8]. Anti-
inflammatory agents, such as ramipril and indomethacin, reduce the number of activated 
microglia in the hippocampus and/or perirhinal cortex and prevent radiation-induced cognitive 
impairment in rodents [9]. However, there is evidence that the reduction of radiation-induced 
brain injury is not necessarily associated with the change in number of activated microglia. The 
anti-inflammatory agent, L-158, 809, has no effect on microglial activation, but still prevents 
radiation-induced cognitive impairment [10]. Orthotopic injections of fetal neuronal stem cells 
that form new neurons without affecting the number of activated microglia reverse radiation-
induced cognitive impairment in rodents [11]. Thus, the exact role that activated microglia play 
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in generating late delayed radiation-induced brain injury, including cognitive impairment, is still 
an open question. 
The vascular injury hypothesis 
It has been suggested that vascular damage leads to ischemia and, secondarily, to white matter 
necrosis. Many studies have reported radiation-induced vascular structural changes, including 
vessel wall thickening, vessel dilation, and endothelial cell nuclear enlargement [12, 13]. 
Quantitative studies in irradiated rat brains have also demonstrated time- and dose-dependent 
reductions in the number of endothelial cell nuclei, blood vessel density, and blood vessel length 
[12, 14]. Moreover, white matter necrosis occurs in boron neutron capture studies where nearly 
all of the radiation damage is to the vasculature [15]. In contrast, radiation-induced necrosis has 
been reported in the absence of vascular changes [13]. Also, the PPARγ agonist, pioglitazone, 
and the ACE inhibitor, ramipril, which prevent radiation-induced cognitive impairment in the rat, 
do not reverse the reduction in vascular density and length that occurs after radiation treatment. 
Consequently, vascular damage is not the only contributor to the late delayed radiation-induced 
injury. 
To sum, there is no single cell or tissue associated with either the glial or vascular injury 
hypotheses that can fully explain the development of RN. The late delayed radiation-induced 
injury is more likely developed due to dynamic interactions between the multiple cell types in 
the brain [16]. Vascular endothelial cells, oligodendrocytes, astrocytes, microglia, and neurons 
are all actively involved in the development of RN that, theoretically, allow one to change the 
response/outcome by intervening at numerous points in the process to prevent or ameliorate the 
development of RN. 
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1.2.1.2 Diagnosis of radiation necrosis 
The clinical presentation and radiological appearance of radiation necrosis is remarkably similar 
to that of recurrent tumor. Distinguishing between these two clinical different entities is a 
significant challenge for treating physicians. Various imaging techniques have been investigated 
for differentiation of recurrent tumor and necrosis. The following is a discussion of the imaging 
modalities utilized to diagnosis RN. 
Conventional MRI 
Conventional, anatomic MRI, refers to T1-weighted post-gadolinium enhanced imaging and T2-
weighted/fluid-attenuated inversion recovery (FLAIR) imaging. Details about these two methods 
will be provided later. T1-weighted post-gadolinium enhanced imaging is a non-specific 
biomarker of BBB breakdown, which can result from post-operative inflammation, seizures, 
tumor recurrence, radiation necrosis or other adjuvant treatment effects. The enhancement on T2-
weighted image is associated with increased water content in tissues, and can result from 
necrosis or recurrent tumor. Some studies have suggested that the pattern of the enhancement 
may aid in the differentiation between necrosis and recurrent tumor. The morphologic features of 
enhancement such as Swiss cheese and soap bubble enhancement have been suggested to be 
more consistent with radiation necrosis [17]. In addition, a combination of lesion multiplicity, 
corpus callosum invasion, and sub-ependymal spread has been noted to be correlated with tumor 
recurrence [18]. The lesion quotient, which is the ratio of the lesion area on T2-weighted image 
divided by the total area of enhancement on contrast-enhanced T1-weighted image, has been 
reported to separate tumor from necrosis [19]. Although these finding may improve the 
diagnostic accuracy, the limitation of diagnosis based solely on conventional MRI is well 
documented [20]. 
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Diffusion weighted imaging and (DWI) and diffusion tensor imaging (DTI) 
In biological tissue, structural barriers such as cell membranes and myelin can restrict the 
mobility of water molecules or favor the movement of water molecules in a specific direction. 
The magnitude and direction of free water movement are quantified with DWI and DTI, 
respectively, by calculating apparent diffusion coefficient (ADC) for magnitude and 
fractional/relative anisotropy for direction [21]. Recurrent tumor often has high cellularity, which 
slows the movement of water molecules (decreased ADC), while necrosis exhibits region of low 
cellularity and, consequently, increased ADC. Several small cohort studies showed the potential 
of ADC measurement for differentiating between tumor and necrosis [22-24]. But the presence 
of edema, which has a high ADC, in both lesions complicates the use of diffusion measurements 
[25, 26]. Further, primary malignant brain tumors usually show lower cellularity and, 
consequently, larger ADC than normal tissue. The sensitivity and specificity of DWI and DTI 
need to be more fully characterized. 
MR perfusion imaging 
Perfusion-weighted MRI measures perfusion, including blood flow and relative cerebral blood 
volume (rCBV) [27]. As a result of increased metabolic activity and angiogenesis due to 
upregulation of VEGF, hyperperfusion is usually seen with recurrent tumor [28, 29]. In contrast, 
CBV decreases in necrotic regions due to occlusive vasculopathy [30]. A prospective study of 20 
patients indicated that an enhancing lesion with a normalized rCBV ratio lower than 0.6 is 
suggestive of radiation necrosis, and an rCBV value higher than 2.6 suggests tumor recurrence 
[31]. When the normalized rCBV ratio is between 0.6 and 2.6, perfusion imaging does not have 
sufficient sensitivity and specificity to distinguish tumor from necrosis. However, a fast growing 
tumor could exceed its blood supply and result in a state of hypoperfusion. Also, it is hard to 
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estimate the perfusion in a mixed necrosis/tumor region [32]. Further, anti-angiogenesis therapy, 
a commonly used tumor treatment [33], can change the perfusion in tissue, thereby complicating 
the interpretation of the results from perfusion-weighted MRI. 
Magnetic resonance spectroscopy (MRS) 
Proton MR spectroscopy determines the metabolic profile in tissue and has been widely 
investigated for differentiation between recurrent tumor and radiation necrosis [34-37]. It has 
been suggested that a low concentration of creatine (Cr) in tissue is more likely correlated to 
radiation necrosis, while a high concentration of choline (Cho) is associated with tumor 
progression [38-40]. As a result, the ratio of Cho and Cr provides a useful variable for recurrent 
tumor diagnosis with high sensitivity and high specificity. However, these studies are all human 
studies and limited by the lack of histology confirmation. The relatively low spatial resolution 
for the current MRS imaging is also a shortcoming, especially for cases of heterogeneous lesions 
consisting of both tumor and necrosis [36].  
Molecular MR imaging 
Amide proton transfer (APT) imaging, a specific chemical exchange-based saturation transfer 
MRI technique, which can be used to detect the amide protons of endogenous, low-concentration 
mobile proteins and peptides in tissue, has been utilized to differentiate radiation necrosis from 
recurrent tumor [41]. The APT imaging signal in tissue is primarily related to two factors: the 
mobile amide proton content and the amide proton exchange rate. Tumors have a higher cellular 
content of proteins and peptides than normal tissue, showing hyperintensities on APT images. 
Radiation necrosis, conversely, exhibits the loss of mobile cytosolic proteins and peptides, 
showing hypointensities on APT images. APT imaging has been limited by its poor multi-slice 
capability, with single slice imaging being used in most of the APT studies.     
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Computerized tomography (CT) 
CT is a conventional imaging technique, available at most hospitals, and CT scans are easy to 
perform. But CT scans rarely distinguish between recurrent tumor and RN [42]. Both types of 
lesions are typically hypo or iso-intense to brain on non-contrasted CT images. With 
administration of contrast, the solid component of the lesion will generally be enhanced [43, 44].  
Nuclear medicine scans  
Both SPECT and PET have been utilized for differentiating between recurrent tumor and 
necrosis in many patients. SPECT scans use radionuclide tracers to assess lesions for their degree 
of metabolic activity indirectly by measuring uptake of a specific tracer within the tissue, which 
is elevated in metabolically active cells, including inflammatory and tumor cells. Increased 
uptake also tends to indicate increased cellularity. Necrosis has no significant metabolic activity 
and should have minimal or no radiotracer uptake [45]. Thallium-201 has been reported to 
evaluate the degree of malignancy or cellular activity quantitatively within the region of interest 
[46]. Various other radiotracers have been investigated, including 99mTc-hexamethy-propylene-
amine oxime (99mTc-HMPAO), and 99mTc-sestamibi. Using SPECT, several groups have 
reported sensitivity of more than 90% in the detection of tumor recurrence, but with specificities 
closer to 60% [47]. Reports of patients with thallium-avid cerebral RN raise questions about the 
clinical utility of these techniques [48, 49]. PET can be used to measure glucose metabolism 
within the brain, using an 18F analog such as fluorine-18 fluorodeoxyglucose (18F-FDG). RN 
should characteristically have low glucose consumption because of the absence of metabolically 
active cells. A near 100% accuracy in a large series of glioma patients has been reported using 
18F-FDG PET scans [50, 51]. Various other investigators have shown less robust sensitivities of 
85% and specificities of 80% [52-54]. However, these results lacked histopathological validation.  
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1.2.1.3 Management of radiation necrosis 
Clinicians have had few options for therapeutic invention when patients develop symptomatic 
radiation necrosis. The following is a discussion of the current managements used to 
mitigate/protect against RN. 
Medical treatment 
Corticosteroids play a significant role in the medical management of radiation necrosis by 
counteracting the radiation-induced vascular endothelial damage and suppressing inflammation 
[55]. However, prolonged treatment with corticosteroids is often employed, and is complicated 
by Cushingnoid side-effects, including weight gain, myopathy, immunosuppression, psychiatric 
disturbances, and occasionally arthritic sequelae, such as avascular necrosis affecting the 
shoulders and hips [56].  
Hyperbaric oxygen (HBO) treatment has also been considered as a therapeutic modality. It 
involves breathing pure oxygen that has been pressurized at 2-3 times normal atmospheric 
pressure. The tissue oxygen pressure increases under these conditions, which potentiates 
angiogenesis, fibroblast and osteoblast proliferation, and collagen formation. The benefit of HBO 
in the treatment of RN has been reported in several reports [57-59]. But most of these studies are 
small, retrospective, and most patients received steroids concurrently [57, 58]. In addition, HBO 
is cumbersome to deliver, expensive, and available in only a few medical centers.  
Bevacizumab, a humanized monoclonal antibody against VEGF [60], has been reported to 
substantially decrease the effects of radiation necrosis [61-64]. A recent randomized double-blind 
study of bevacizumab therapy for the patients with radiation necrosis provided evidence of its 
efficacy in mitigating radiation necrosis [64]. However, these studies relied on MR imaging, and, 
11 
 
in particular, T1 post-gadolinium enhancement to characterize radiation necrosis, which is 
complicated by the presence of recurrent tumor. Also, because it is generally not possible to 
correlate time-course MR observations with histologic findings in patients, these human studies 
lack information regarding the mechanism of action of bevacizumab. Thus, further studies are 
needed to validate the effects and mechanisms of bevacizumab in the treatment of radiation 
necrosis. 
Surgical management 
Surgical resection of necrotic tissue reduces mass effect, edema and lowers intracranial pressure, 
resulting in lasting clinical improvement in the majority of patients. Although it is the only 
definitive treatment of brain necrosis, it is often not possible due to the location of the necrosis in 
eloquent regions of the brain. 
Laser interstitial thermal therapy (LITT) 
As discussed in section 1.2.1.1, upregulation of VEGF likely plays an important role in the 
development of RN. It has been suggested that the perinecrotic region of gliosis is responsible 
for most of the VEGF release. As a result, targeting this gliotic region with LITT can remove 
most of the active VEGF and replace these lesions with a region of inactive, factor-depleted 
coagulative necrosis. A recent study demonstrated the possibility of using LITT to safely treat a 
patient with cerebral RN [65]. 
  
1.2.2 Magnetic Resonance Imaging (MRI) in characterizing radiation necrosis 
MRI is a medical imaging technique used extensively to visualize detailed internal structures of 
the body. It makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of 
atoms inside the body. MRI provides excellent contrast between the different soft tissues of the 
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body, which makes it especially useful in monitoring the brain, muscle, the heart, and cancers, 
compared with other imaging modalities such as CT and x-ray imaging. The following 
introduces the basic working theory of MRI and all the MR methods used in my PhD research. A 
more detailed discussion of the content of section 1.2.2.1 can be found in most classical 
textbooks on the subject [66, 67].  
1.2.2.1 Introduction to MRI basics  
Nuclear spin 
Spin is a form of angular momentum. However, it is not produced by a rotation of the particle, 
but is an intrinsic property of the particle itself. The spin angular momentum S of any physical 
system and the component of S measured along any direction are: 
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Where h is Planck’s constant and s is the spin quantum number. The spin quantum number takes 
values of the form N/2, where N can be any non-negative integer. The spin quantum number of 
protons, the most common signal source in MRI experiment, is 1/2.  
Particles with spin possess an intrinsic magnetic moment. The magnetic moment is proportional 
to the spin angular momentum: 
Sγµ =  
For atomic nuclei, the proportionality constant γ is called the gyromagnetic ratio. The magnetic 
energy of an object depends on the interaction between its magnetic moment and the external 
magnetic field: 
BE

•−= µ  
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Assuming that the external magnetic field B is applied along z direction, the magnetic energy of 
spin-1/2 nuclei can be simplified as: 
zzz B
hBSE γ
π
γ
4
±=−=  
There are two energy states, one representing alignment parallel to the field, another anti-parallel. 
According to Boltzmann statistics, the population ratio of the two states is determined by: 
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Where k is the Boltzmann constant and T is the absolute temperature. The spin population 
difference between two energy states generates a net magnetization parallel to the field, which is 
the source of MR signal. With the common temperature in biological tissues and currently 
available magnets, this population difference is extremely small—on the order of 1 in a million 
spins. Fortunately, the human body is made up of approximately 60% water and each molecule 
of water (H2O) contains two hydrogen atoms. These hydrogen atoms provide a sufficient signal 
to enable MRI experiments. 
Free induction decay 
Spin is a quantum-mechanical property. However, for describing the mechanism of MR signal 
generation, it is often convenient to consider the analogue of spin in classical physics. Just as a 
spinning top precesses around the gravitational field, nuclear spin precesses about the axis of the 
external magnetic field B0. The precession frequency is ω0=γB0, also known as the Larmor 
Frequency.  
In the presence of an external magnetic field B0, nuclear spins at equilibrium produce a net 
magnetization M0 along the B0 field (Z direction). In MR, the detectors are only able to measure 
magnetization processing in the plane perpendicular to the static magnetic field.  
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An electromagnetic radio frequency (RF) pulse in the XY plane is applied at or near the Larmor 
Frequency to nutate the net magnetization towards the XY plane. At the quantum level, nuclear 
spins absorb the RF energy and transition to the higher energy state. Once the RF pulse is turned 
off, three things begin to happen simultaneously: 
1. The magnetization in the XY plane continues to precess in transverse plane around the B0 
field, and induces an oscillating electric current in the wire, which can be picked up by a 
receiver coil and becomes NMR signal, also known as free induction decay, or FID.  
2. The energy absorbed by the excited spins is released back into the surrounding lattice 
(spin-lattice relaxation), reestablishing thermal equilibrium. In the classical description, 
the Z component of the magnetization (Mz) grows back to M0. The time course of spin-
lattice relaxation can often be described by an exponential curve. The recovery rate is 
characterized by the relaxation time constant T1, which is unique to every tissue and 
varies with magnetic field strength. This uniqueness in Mz recovery rates is what 
generates contrast enabling MRI to differentiate between different types of tissue. In MRI 
experiments, the signal of a single voxel contains spins having different T1. The 
longitudinal relaxation is then described by muti-exponential curve. 
3. Initially in phase, the excited spins begin to dephase. How fast a spin precesses depends 
on the magnetic field that it experiences. Interactions between spins generate fluctuating 
magnetic fields at the sites of the nuclear spins, leading to different precession 
frequencies. The frequency differences cause a cumulative loss of phase across the 
excited spins, and results in an overall loss of signal. The signal decay due to spin-spin 
relaxation is often also described by an exponential curve, whose decay rate is 
characterized by the relaxation time constant T2, which is unique to every tissue and is 
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determined primarily by its chemical environment, with little dependence on field 
strength. In reality, many fixed factors, such as the imperfect magnet and field distortion 
resulting from air/tissue interfaces, create inhomogeneities of a magnetic field and cause 
signal to decay even quicker. The sum total of all of these random and fixed effects is 
called T2* relaxation.   
Spin/gradient echo 
The signal decay due to fixed effects (e.g., the imperfect magnet and field distortion resulting 
from air/tissue interfaces) can be compensated for using a spin echo. The pulse sequence diagram 
for a spin echo (SE) experiment is shown in Figure 1.1: 
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Figure 1.1. Spin echo pulse sequence diagram. 
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The net magnetization is flipped by a 90 degree RF pulse into the XY plane; 
A time of TE/2 (TE refers to time to echo) is allowed to elapse while the spins dephase due to T2* 
effects; 
At t = TE/2, a 180 degree RF pulse is applied to flip the dephased vectors; 
Another TE/2 time is allowed to pass while the vectors rephase; 
At t = TE, the vectors have rephased and a spin echo forms. 
The signal intensity equation in a standard spin-echo sequence is expressed as follows: 
)]/exp(1[)/exp( 1201 TTRTTESS WT −−⋅−⋅= , 
where S0 is the proton density and TR is the repetition time. This expression indicates that T1-
weighted, T2-weighted and proton density weighted (PDW) images can be generated depending 
on the choice of values for TR and TE. Long TR and short TE yield PDW images; long TR and 
long TE yield T2-weighted images; short TR and short TE yield T1-weighted images. 
The formation of gradient echo (GE) does not utilize the 180 degree rephasing RF pulse. As a 
result, the GE signal suffers from T2* decay. However, small flip angles are employed, which, in 
turn, allow very short repetition time (TR) values, thus decreasing the scan time.     
 
1.2.2.2 MR contrast agent/tracers 
MRI techniques exist that utilize both exogenous and endogenous tracers. In this dissertation, the 
focus is on exogenous MR contrast agents (CA). Interestingly, MR CAs are not directly MR 
detectable, but their effects are indirectly observed. For example, a T1-weighted contrast-
enhanced image is an image of the bulk water in which a hyperintense region due to water with 
short, CA-induced T1 reflects high CA concentration at that region. The signal intensity of these 
contrast-enhanced MR images includes anatomic information and dynamic data may include 
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more information.      
The vast majority of all exogenous MR CAs, used both clinically and preclinically, utilize the 
gadolinium ion Gd3+. These chelated gadolinium compounds (examples of currently used 
chelates are shown in Figure 1.2) affect the nuclear magnetic relaxation times of the water 
protons in surrounding tissues. The relaxivity enhancement of water protons in aqueous solutions 
of Gd3+ complexes arises from time fluctuation of the dipolar coupling between the electron 
magnetic moment of the metal ion and the nuclear magnetic moment of the solvent nuclei. This 
interaction is traditionally described with a two-component, inner sphere and outer-sphere [68, 
69]. Inner sphere refers to the water molecules present in the coordination sites of the Gd3+ ion 
and outer sphere involves all the solvent molecules diffusing past the complex. The measured 
relaxation rate (Robs) can be written as the sum of the relaxation rate of the solvent (Rw) in the 
absence of the paramagnetic complex, inner-sphere relaxation rate (Rinner) and outer-sphere 
relaxation rate (Router): 
Robs = Rw + Rinner + Router                                                    
Further, the sum of Rinner and Router is proportional to the concentration of Gd3+ ions.       
Robs = Rw + constant*[Gd3+]                          ,                       
where the constant is relaxivity, a measure of the effectiveness of the CA. 
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Figure 1.2. Example chelates for Gd-based contrast agents. 
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1.2.2.3 T1-weighted post-gadolinium and T2-weighted imaging 
As mentioned, the time constant T1 is unique to every tissue and can be affected by the 
exogenous MR CA. This enables T1 as a very important contrast in MR imaging. Water with a 
short T1, either caused by high CA concentration at that location or a short native T1, appears 
bright on a T1-weighted post-Gd image. Chelated gadolinium compounds, the most commonly 
used CA, cannot pass the intact blood-brain barrier (BBB) in normal tissue because they are 
hydrophilic, but can leak into the surrounding tissue through a compromised BBB. Thus, T1-
weighted post-Gd imaging is a commonly used biomarker to identify BBB breakdown, which 
can result from post-operative inflammation, tumor recurrence, radiation necrosis or other 
adjuvant treatment effects. A large number of studies demonstrate the sensitivity of T1-weighted 
post-Gd to various lesions [70-73]. In contrast, the specificity is poor. For example, radiation 
necrosis and recurrent tumor are both highlighted as bright regions on T1-weighted post-Gd 
images [20]. Fortunately, our animal model is a radiation necrosis-only model. The onset, 
progression and therapeutic response of radiation necrosis in chapter 2 and 4 were well 
characterized by T1-weighted post-Gd imaging. Chapter 3 focuses on the validation of the 
efficacy of anti-VEGF therapy in the treatment of radiation necrosis. Anti-VEGF therapy can 
decrease the permeability of abnormal vasculature, and can potentially decrease the intensity of 
necrotic regions in T1-weighted post-Gd images because a longer time is needed to accumulate 
the sufficient CA in the necrotic region. To avoid the confusion between decrease of vasculature 
permeability and decrease of necrosis, T1-weighted post-Gd data were not used to demonstrate 
the mitigative effect of anti-VEGF antibodies.  
In the clinical setting, T2-weighted images generally highlight pathology. T2-weighted imaging 
has been widely utilized to locate various tumors due to the increased ‘free’ water content in 
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tumor, which has longer T2 than that of tissue water [74-78]. Although T2-weighted imaging 
cannot differentiate radiation necrosis from recurrent tumor, it can be used to characterize the 
progression of radiation necrosis in our necrosis-only animal model.  
1.2.2.4 Dynamic Contrast Enhanced imaging (DCE) 
DCE is a noninvasive quantitative method of investigating microvascular structure and function 
by tracking the pharmacokinetics of injected paramagnetic contrast agents as they pass through 
the lesion vasculature [79]. This technique is sensitive to alterations in vascular permeability, 
extracellular extravascular and vascular volumes, and blood flow.  
In DCE measurement, an intravenous bolus of gadolinium contrast agent enters tissue arteries, 
passes through capillary beds and then drains via veins. In normal brain tissue, the paramagnetic 
ions do not enter extravascular space and pass through the tissue vasculature rapidly compared 
with the usual temporal resolution of DCE. As a result, the T1-weighted DCE signal does not 
change with time. In tumor, gadolinium ions leak into extravascular extracellular space and leads 
to an increase in T1-weighted signal intensity within each single voxel. The degree of signal 
enhancement depends on physiological and physical factors, including tissue perfusion, the 
arterial input function (AIF), which is the concentration-time course of contrast agent in the 
artery supplying the vascular bed, the capillary surface area, capillary permeability and the 
volume of the extracellular extravascular leakage space (EES). The T1-weighted DCE signal 
intensity will return to its initial value as the ions drain via veins.  
T1-weighted DCE signal can be converted into contrast agent concentration assuming that the 
relaxation rate constant, R1 (=1/T1), is proportional to the contrast agent concentration. The time 
course of changes in concentration is described as [80]: 
)( tep
transt CVCK
dt
dC
−=  
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Where Ve is the volume of extravascular extracellular space, Ktrans is the volume transfer rate 
between blood plasma and Ve, Ct is the concentration of contrast agent in the tissue and Cp is the 
concentration of contrast agent in the blood, also known as arterial input function (AIF). High 
Ktrans values indicate that the BBB is not intact, while low Ktrans values indicate that the BBB is 
intact. It is evident that both Ktrans amd Ve can be obtained if the Ct and AIF are measured 
accurately. Ideally, the AIF is a “delta” function, but, in practice, it is more like a bell curve due 
to the time to inject contrast agent and the fact that the agent is mixed with blood. AIF 
measurement has a major impact on DCE data analysis. Unfortunately, direct AIF measurement 
is technically demanding and, at best, obtained from a nearby large artery which may differ from 
the vessel supplying the tissue of interest. There have also been attempts to use a mathematical 
function describing AIF [81]. In our DCE experiments conducted in mouse brain, it is hard to 
define a high quality AIF region. Instead, a reference region approach was employed [82, 83]. 
The reference region is composed of muscle outside the skull. The reference region (RR) model 
establishes a relationship between Ct and CRR (CA concentration in the reference region) that 
allows the derivation of a model that is independent of Cp: 
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Where Ktrans,RR and Ktrans,t are Ktrans for the RR and tissue of interest, respectively; Ve,RR and Ve,t 
are Ve for the RR and tissue of interest, respectively. With fixed Ktrans,RR and Ve,RR, both Ktrans,t 
and Ve,t are obtained by performing a two-parameter fit.  
In this dissertation, in order to validate the hypothesis that anti-VEGF antibodies repair the 
abnormal vasculature in necrotic region, Ktrans maps for non-antibody-treated and antibody-
treated mice at 13 weeks following a single 50-Gy dose of radiation were compared. Further, 
Ktrans maps pre and post a single antibody treatment for the same animal were compared to study 
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the immediate effect of the anti-VEGF antibody. 
   
1.2.2.5 Quantitative blood oxygen level dependent (qBOLD) 
Remarkable changes in cerebral blood flow and oxygen consumption are observed in the region 
of tumor. Quantitative evaluation of these changes, such as cerebral blood flow (CBF), cerebral 
blood volume (CBV), oxygen extraction fraction (OEF) and other important hemodynamic 
parameters, has been shown to provide in vivo functional information [84, 85] and increase the 
accuracy of tumor diagnosis [86-88]. Benefits of the measurements targeting these hemodynamic 
parameters in differentiating recurrent tumor from radiation necrosis have been reported [89-91]. 
However, there is no current clinically accepted MRI-based method for measuring OEF, the 
major parameter characterizing brain hemodynamics, in vivo. Currently, the only clinically 
accepted OEF measurement relies on PET techniques [92]. But the PET-based methods are 
limited in human study and clinical practice due to their low spatial resolution and the need for 
radionuclides. 
qBOLD imaging technique (details discussed in chapter 5), recently developed by Dr. Dmitriy 
Yablonskiy, provides an MRI-based method to measure deoxyhemoglobin-containing (veins and 
ravenous section of capillaries) cerebral blood volume fraction (dCBV) and OEF in vivo. 
qBOLD has been validated in phantoms [93]. In vivo human studies [94] have also demonstrated 
the feasibility of this approach, but also revealed that obtaining reliable results requires high 
SNR data and accurate correction for macroscopic magnetic field inhomogeneities. Therefore, 
qBOLD could be potentially useful in differentiating tumor from radiation necrosis. In this 
dissertation, qBOLD was investigated in order to evaluate the feasibility of this approach in 
characterizing radiation necrosis in mouse brain.  
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1.2.3 Animal model of radiation necrosis 
Animal model of specific disease provides a significant opportunity for diagnostic and 
therapeutic studies with imaging findings directly supported by correlative histology and 
statistical power, which allows positive results to be readily translated to clinical research 
investigation. Animal models of brain tumors and stroke have been extensively reported in the 
literature [95]. Also, there have been attempts to induce radiation necrosis in the brains of large 
animals, such as pig [96] and cat [97], using various high-dose irradiation, including linear 
accelerator radiosurgical device and electron beam. In contrast, few small-animal models of 
radiation necrosis in brain tissue had been reported [98]. Previous animal models were developed 
primarily in rats [99, 100]. Irradiation of small animals, particularly mice, was performed by 
irradiating a large portion of the animal's body with selective shielding, rather than by directing 
radiation doses to focal targets. These approaches do not allow specific targeting of focal regions 
of mouse brain, a sine qua non for such studies.  
The recent development of a conformal preclinical irradiation system demonstrated that high-
dose, focal, fractionated brain irradiation in small animals is feasible. We recently described a 
murine model of radiation necrosis using micro-radiotherapy (microRT) system [101]. The 
progression of necrosis was characterized by contrast-enhanced T1- and T2-weighted MRI and 
histology reflected changes typically seen in radiation necrosis in human. A brain radiation 
necrosis model in rats has been established using a small animal radiation research platform, in 
which the necrosis began to appear at about 5 months post a single 40-Gy dose of x-ray radiation 
[41]. A mixed rodent model of radiation necrosis and tumor has been developed using a 4-mm 
radiosurgery cone to deliver a single 60-Gy dose of radiation to an implanted GBM cell line in 
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the brains of rats [102]. Histological evaluation of the brains of rats with implanted irradiated 
GBM cells showed central liquefaction necrosis in high-dose regions, consistent with necrosis 
and viable tumor growth in low-dose regions.  
Although these studies demonstrated the feasibility of generating radiation necrosis in mouse/rat 
brain employing stereotactic radiosurgery, they were performed on a small number of animals. 
Further, determinants of the onset and progression of radiation necrosis in that specific animal 
model (e.g., radiation dose and fractionation), which are crucial for the design of studies aimed at 
developing methods to identify/detect, monitor, protect against, and mitigate radiation necrosis, 
have not been well investigated.  
Severity of radiation injury is affected by several factors, including total dose absorbed (dose rate 
and duration of exposure time), number of exposures, interval between exposures, extent and 
part of body irradiated, and age of subject exposed [103]. The radiation dose-response 
relationship has been demonstrated graphically through a curve that maps the biologic effects 
observed in relation to the dose of radiation received. The curve is either linear or non linear and 
depicts either a threshold dose or a non-threshold dose [104]. Currently, the committee on the 
Biological Effects of Ionizing Radiation (BEIR) recommends the use of the linear, non-threshold 
curve of radiation dose-response for describing most types of cancer [105-107], which implies 
that the biologic response is directly proportional to the dose and any radiation dose will produce 
a biologic effect. Also, the BEIR committee believes the linear-quadratic, non-threshold curve is 
a more accurate reflection of biologic effects at low-dose levels from low-linear-energy-transfer 
(low LET), such as X and gamma rays. The risk of radiation-induced cancer (e.g., leukemia, 
breast cancer), and heritable damage are considered to follow this curve. The sigmoid, threshold 
curve of radiation dose-response is commonly employed in radiotherapy to demonstrate high-
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dose cellular response. As shown in Figure 1.2, there is a minimal dose of radiation below which 
observable effects will not occur. At high radiation doses, the curve gradually levels off because 
the irradiated living specimen or tissue dies before the observable effects appear. An ideal 
protective agent will move the dose-response curve for normal tissue to the right without 
affecting that for the lesion. The therapeutic ratio is determined by the horizontal separation 
between the curves. 
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Figure 1.3. Sigmoid dose-response curves showing the relationship between increasing dose and 
lesion control probability (yellow) and normal tissue complication probability (blue). The 
therapeutic ratio is determined by the horizontal separation between the curves. An ideal 
protective agent will move the dose-response curve to the right without affecting the lesion 
control curve. 
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Radiation necrosis has been suggested to follow a sigmoid, threshold curve [108]. As a result, the 
therapeutic effect of any neuroprotective/mitigative agents could be maximized in animals 
irradiated with radiation doses corresponding to the steep rise in the curve. In this dissertation, a 
novel animal model of radiation necrosis was developed. Injuries were produced in a large 
number of mice and critical determinants (dose and fractionation) governing the onset and 
development of injury were elucidated.  
 
1.2.4 Gamma-Knife irradiation 
As mentioned, high-dose, focal, fractionated brain irradiation is the key for developing an animal 
model of radiation necrosis. The Leksell Gamma Knife® Perfexion™ (Elekta; Stockholm, 
Sweden; http://www.elekta.com/), is a state-of-the-art unit used for stereotactic irradiation of 
patients with diseased brain tissue.  
A Gamma Knife typically contains 192 cobalt-60 sources of approximately 30 curies each, 
placed in a circular array in a heavily shielded assembly. Gamma Knife therapy uses doses of 
radiation to kill cancer cells and shrink tumors, delivered precisely to avoid damaging healthy 
brain tissue. The device is able to accurately focus multiple beams of gamma radiation on one or 
more tumors. Each individual beam is of relatively low intensity, so the radiation has little effect 
on the intervening surrounding healthy brain tissue and is concentrated only at the tumor itself.  
Gamma Knife radiosurgery has become an indispensable tool in the primary and adjuvant 
management of various intracranial pathologies, including meningiomas, pituitary tumors, and 
arteriovenous malformations [109, 110]. But, as a focused treatment, the role of Gamma Knife 
radiosurgery in treating a highly invasive tumor, such as a glioblastoma multiforme (GBM), is 
limited [111]. 
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The device allows reproducible treatment of tumors as small as 1 cm3 and the geometrical 
accuracy is approximately 0.5mm. As the volume of a mouse brain is about 3-4 cm3, gamma 
knife permits high dose, fractionated, hemispherical irradiation of mouse brain. 
The dose of gamma radiation is measured in the unit of gray (Gy), which is defined as the 
absorption of one joule of gamma energy by one kilogram of matter. The gray is defined 
independently of the target material. The absorbed dose for biological tissue at a specific location 
decreases with the distance from the center of radiation focus. The term “xx Gy at the 50% 
isodose” is frequently used to characterize the distribution of gamma radiation in the tissue, 
which indicates the half dose of the maximum dose delivered to tissue.  
In radiation therapy, the amount of radiation varies depending on the type and stage of cancer 
being treated. For curative cases, the typical dose for a solid epithelial tumor ranges from 60 to 
80 Gy, while lymphomas are treated with 20 to 40 Gy. Preventive (adjuvant) doses are typically 
around 45–60 Gy, delivered in 1.8–2 Gy fractions (for breast, head, and neck cancers). In this 
dissertation, more aggressive radiation dose schedules were utilized to ensure a high occurrence 
of radiation necrosis. 
 
1.3 Aims and Outline 
The goals of the investigation are: 
i) Develop a novel Gamma-Knife mouse-model of radiation necrosis and optimize the 
appropriate radiation dosing schemes (total dose, fractionation) for this model; 
ii) Determine the efficacy of bevacizumab (Avastin) and B20-4.1.1, both vascular 
endothelial growth factor (VEGF) inhibitors, as mitigators of radiation necrosis in mice; 
iii) Validate the neuroprotective effect of SB 415286, an inhibitor of glycogen synthase 
30 
 
kinase 3β (GSK-3β), in mouse brain following high-dose radiation treatment;  
iv) Identify and validate qBOLD method as an imaging marker of radiation necrosis.    
Chapter 2 focuses on the development and optimization of an animal model of radiation necosis; 
Chapter 3 and 4 present the mitigation and neuroprotection studies of radiation necrosis in mouse 
brain, respectively. Chapter 5 discusses the possibility of using qBOLD method to characterize 
radiation necrosis. Chapter 6 provides a summary and discusses future studies.  
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Chapter  2 Development and Optimization of a Mouse Model of Radiation Necrosis 
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Introduction  
The management of both benign and malignant central nervous system tumors remains a 
challenging clinical problem, often requiring multimodal therapy, including surgical resection, 
chemotherapy, and radiation. Over the past decade, patient outcomes have benefitted from 
numerous advances, including novel chemotherapeutic agents, improved surgical resection, and 
the use of sophisticated, fractionated, high-dose radiation and radiosurgical methods. Radiation 
effects on non-neoplastic tissue, resulting in acute, early-delayed and late-delayed radiation-
induced neurotoxicity, may complicate the outcomes of radiotherapy. Radiation necrosis (RN), a 
delayed radiation neurotoxicity, can develop in up to 24% of patients receiving focal irradiation 
three or more months following therapy [1]. The incidence of RN may be threefold higher with 
concurrent chemotherapy [3, 112].  
Since the treatment paradigms for recurrent tumor and necrosis are significantly different, the 
differentiation between these two lesions may be critically important for achieving better clinical 
outcomes. Unfortunately, both recurrent tumor and RN have a similar appearance on 
conventional anatomic magnetic resonance imaging (MRI) and computerized tomography (CT) 
scans. A number of advanced imaging techniques, including magnetic resonance spectroscopy 
(MRS), MR diffusion-weighted imaging (DWI), diffusion tensor imaging (DTI) and perfusion 
techniques, positron emission tomography (PET), and thallium single photon emission computed 
tomography (SPECT), have been used to evaluate RN [22, 113-115]. Nonetheless, no single 
imaging modality has been shown to reliably distinguish radiation necrosis from recurrent tumor 
[116]. 
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Clinicians have relatively few good options for therapeutic invention when patients develop 
symptomatic radiation necrosis. Surgical resection of necrotic tissue is often not possible due to 
the location of the necrosis in eloquent regions of the brain. Prolonged treatment with 
corticosteroids is often employed [55], but is complicated by Cushingnoid side effects, including 
weight gain, myopathy, immunosuppression, psychiatric disturbances, and occasionally arthritic 
sequelae, such as avascular necrosis affecting the shoulders and hips [56]. Hyperbaric oxygen 
treatment has also been explored as a therapeutic modality [57, 59], but it is cumbersome to 
deliver, expensive, and available in only a few medical centers. Its benefit has only been shown 
in a small number of cases [58].  
A reproducible animal model of radiation necrosis provides a significant opportunity for 
diagnostic and therapeutic studies with imaging findings directly supported by correlative 
histology and statistical power, which allows positive results to be readily translated to clinical 
research investigation. Animal models of brain tumors and stroke have been extensively reported 
in the literature [117-119]. However, the lack of a well-developed, small-animal model of 
radiation necrosis has significantly hampered the development of diagnostic and therapeutic 
management of RN. Until recently, few small-animal models of radiation necrosis in brain tissue 
had been reported [2, 5], with most previous animal models developed in rats. In the past, 
irradiation of small animals, particularly mice, was performed by irradiating a large portion of 
the animal's body with selective shielding, rather than by directing radiation doses to focal 
targets. These approaches do not allow specific targeting of focal regions of mouse brain, a sine 
qua non for such studies.  
The recent development of a conformal preclinical irradiation system demonstrated that high-
dose, focal, fractionated brain irradiation in mice is feasible. We recently described a murine 
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model of radiation necrosis using a micro-radiotherapy (microRT) system [101].  The 
progression of necrosis was characterized by contrast-enhanced T1- and T2-weighted MRI and 
histology reflected changes typically seen in radiation necrosis in human.  A brain radiation 
necrosis model in rats has been established using a small animal radiation research platform, in 
which the necrosis began to appear at about 5 months post a single 40-Gy dose of x-ray radiation 
[41]. A mixed rodent model of radiation necrosis and tumor has been developed using a 4-mm 
radiosurgery cone to deliver a single 60-Gy dose of radiation to an implanted GBM cell line in 
the brains of rats [102]. Histological evaluation of the brains of rats with implanted irradiated 
GBM cells showed central liquefaction necrosis in high-dose regions, consistent with necrosis 
and viable tumor growth in low-dose regions. Although these studies demonstrated the feasibility 
of generating radiation necrosis in mouse/rat brain using focal brain irradiation, they were all 
performed on small cohorts of animals. Determinants of the onset and progression of radiation 
necrosis, including radiation dose and fractionation, which are crucial for the design of studies 
aimed at developing methods to identify/detect, monitor, protect against, and mitigate radiation 
necrosis, have not been well investigated. 
The Leksell Gamma Knife (GK) Perfexion, a state-of-the-art unit used for stereotactic irradiation 
of patients with benign and malignant brain tumors, enables reproducible treatments of a small 
volume (1 cm3 or less) with a precision of less than ±0.5 mm in stereotactic space. We 
hypothesized that this technology could be used to create a murine model of RN, using 
hemispheric irradiation in a dose and fractionation scheme patterned after therapeutic doses of 
radiation used clinically. An essential component of critically evaluating animal models of 
disease and pathology is correlation of findings with goal-standard histology. Herein, we report 
on the development of a semi-quantitative histologic scoring system for evaluation of the extent 
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and severity of tissue injury in our mouse model of RN. In total, the goals of this work were to 
develop a GK-based murine model of radiation necrosis, to characterize the development of RN 
using MRI protocols and histologic evaluation, and to elucidate the critical determinants (i.e., 
radiation dose and fractionation scheme) governing the onset and progression of tissue injury. A 
well-characterized animal model of RN will provide a platform for studies to optimize dose and 
fractionation schemes for future clinical treatment protocols.   
Materials and Methods 
Animals 
All studies were performed in accordance with the guidelines of the IACUC and in accordance 
with protocols approved by the Washington University Division of Comparative Medicine that 
met or exceeded American Association for the Accreditation of Laboratory Animal Care 
standards. Female Balb/c mice were used for the study and observed daily and weighed weekly 
to ensure that interventions were well tolerated. 
Small-animal Irradiation 
Mice were irradiated with the Leksell Gamma Knife® (GK) Perfexion™ (Elekta; Stockholm, 
Sweden; http://www.elekta.com/). Mice were supported on a specially designed platform 
mounted to the stereotactic frame that attaches to the treatment couch of the GK. Mice were 
anesthetized with a mixture of ketamine (25 mg/kg), acepromazine (5 mg/kg) and xylazine (5 
mg/kg), injected intraperitoneally 5 min before the start of irradiation. Four cohorts of female 
Balb/c mice (n=15 each) were irradiated with four different dose schedules: 60-Gy in a single 
fraction, 60-Gy in three fractions, 50-Gy in a single fraction and 45-Gy in a single fraction, as 
described below. The resulting brain parenchymal changes were characterized by both MRI and 
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histology. 
MR Imaging 
Images were collected in an Agilent/Varian (Santa Clara, CA) 4.7-T small-animal MR scanner 
equipped with a DirectDriveTM console. The scanner is built around an Oxford Instruments 
(Oxford, United Kingdom) 33-cm, clear-bore magnet equipped with 21-cm inner diameter, 
actively shielded Agilent/Magnex gradient coils (maximum gradient, 28 G/cm; rise time 
approximately 200 ms) and International Electric Company (IEC; Helsinki, Finland) model A-
240 amplifiers (300 V and 300 A). 
MRI data were collected using an actively decoupled coil pair: 1.5-cm outer diameter surface 
coil (receive) and a 9-cm inner diameter Helmholtz coil (transmit). Before the imaging 
experiments, mice were anesthetized with isoflurane/O2 (3% [vol/vol]) and maintained on 
isoflurane/O2 (1% [vol/vol]) throughout the experiments. Mice were restrained in a laboratory-
constructed Teflon head holder with ear bars and a tooth bar. To maintain their body temperature 
at approximately 37°, mice were placed on a water pad circulating warm water. Mice were 
injected intraperitoneally with 0.5 mL Omniscan (gadodiamide; GE Healthcare, Princeton, NJ) 
contrast agent, diluted 1:10 in sterile saline, immediately prior to positioning in the magnet. 
Mice that received 60-Gy of radiation, in either single or three fractions, or 50-Gy of radiation 
were imaged 4, 8, and 13 weeks post-irradiation. Mice that received 45-Gy of radiation were 
imaged 10, 13, 16, 19 and 22 weeks post-irradiation. The time interval between adjacent imaging 
sessions was chosen to ensure observable progression of RN on anatomic MR images. Mice 
were sacrificed immediately after the last imaging point (13 and 22 weeks post-irradiation for 
mice receiving 50/60-Gy and 45-Gy of radiation, respectively). End points were selected because 
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by these times, the majority of mice showed a significant deterioration in physical condition, 
including loss of more than 20% bodyweight and/or obvious behavioral impairment (such as 
ataxia), as well as significant RN (>30% of the volume of the irradiated hemisphere), as 
determined by MR imaging. Multislice, T2-weighted, spin-echo transaxial images were collected 
beginning ~3 minutes following intraperitoneal injection of 0.5 mL  of MultiHance (gadobenate 
dimeglumine; Bracco Diagnostics) contrast agent, diluted 1:10 in sterile saline, with the 
following parameters: repetition time [TR] = 1.5 s, echo time [TE] = 0.05 s, field of view [FOV] 
= 1.5 x 1.5 cm2, slice thickness = 0.5 mm, 21 slices to cover the whole brain; total acquisition 
time = 12 minutes. Multislice, T1-weighted, spin-echo transaxial images were then collected 
over 5 minutes with the following parameters: TR = 0.65 s, TE = 0.02 s, FOV = 1.5 x 1.5 cm2, 
slice thickness = 0.5 mm, 21 slices to cover the whole brain. 
Measuring Necrotic Volumes Quantitatively by MR Imaging 
Regions of radiation necrosis appeared as hyperintense areas on both contrast-enhanced, T1-
weighted and T2-weighted images. While either set of images could be used for quantitative 
analysis, we chose to calculate necrotic volumes from T2-weighted images, as described 
previously [120]. Briefly, for each set of T2-weighted spin-echo images, regions of interest were 
drawn around the entire brain in several contiguous image slices, chosen to include the entire 
hyperintense region. Each brain was divided along the midline into left (irradiated) and right 
(non-irradiated) hemispheres. The image intensity for each individual pixel in the left hemisphere 
was normalized by the average of the 25 pixels (5 x 5 square) including and immediately 
surrounding its mirror-image pixel in the right hemisphere, and histograms of normalized 
intensity for the irradiated hemisphere were constructed. The same analysis was performed on a 
cohort (n=10) of non-irradiated mice. The histogram of average intensity distribution for non-
48 
 
irradiated subjects is symmetric; 99% of the pixels are distributed in the intensity range 0.6 – 1.4 
about a normalized mean of 1.0. Therefore, an intensity threshold of 1.4 was chosen as the cutoff 
for normal brain tissue. For images of irradiated mice, the number of pixels exceeding this 
threshold serves to measure the necrotic volume. 
Histology 
Selected groups of the mice were sacrificed for histological studies at various times after 
irradiation.  Following intra-cardiac perfusion with 0.1 M Phosphate-buffered saline and 
formalin, each mouse head was then dissected and immersed in formalin for 24 hours. Brains 
were then dissected, processed through graded alcohols, embedded in paraffin, and sectioned in 
coronal planes. Eight-micron-thick tissue sections were stained with hematoxylin and eosin 
(H&E). Briefly, the slides were de-paraffinized with 100% xylene, 100% ethanol, 90% ethanol, 
80% ethanol, and finally distilled water. Nuclei were stained with the alum hematoxylin and 
rinsed with running tap water, differentiated with 0.3% acid alcohol, and rinsed again with tap 
water.  Slides were stained with eosin for two minutes, followed by a series of dehydration steps.  
Other samples were fixed in modified Zenker’s solution and stained, according to standard 
protocols, with either phosphotungstic acid-hematoxylin (PTAH) to demonstrate the presence of 
fibrin in tissue or with trichrome to reveal collagen deposition within the brain.   
Statistical Analysis 
The differences in MR-derived necrotic volumes for mice having different histological scores 
were summarized using means and standard deviations, and compared by one-way ANOVA. Due 
to the relatively large variability in MR-derived necrotic volumes, a logarithm transformation 
was performed to better satisfy the assumption of a normal distribution. The correlation between 
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MR results and histology scores was also assessed using Kendall’s tau correlation coefficient 
[121]. All the tests were two-sided and a p-value of 0.05 or less was taken to indicate statistical 
significance. Statistical analysis was performed using SAS 9.3 (SAS Institutes, Cary, NC).   
Results 
MRI detects radiation necrosis as image hyperintensity in contrast-enhanced T1-weighted 
images 
Representative contrast-enhanced T1-weighted spin-echo images of irradiated mice, covering the 
same anatomic region of the brain and collected at 1, 4, 8, and 13 weeks following a single 50-
Gy dose of radiation, are shown in Figure 1. Hyperintense areas in these images, due to leaky 
vasculature, correspond with regions of radiation necrosis in the brain. MR images begin to show 
hyperintense regions at ~4 weeks post irradiation, and these regions expand significantly in 
extent by 13 weeks, indicating late onset and rapid progression of radiation necrosis. 
Radiation dose schedules affect the onset and progression of radiation necrosis 
Figure 2 shows the progressions of the volumes of MRI-derived necrotic regions for irradiated 
mice, in which mice received four different radiation dose schedules, including 60-Gy in a single 
fraction (red), 60-Gy in three fractions (green), 50-Gy in a single fraction (black), 45-Gy in a 
single fraction (blue). Mice received either 60-Gy or 50-Gy of radiation developed RN at 3-4 
weeks post irradiation and had significant, large RN (>30% of the volume of the irradiated 
hemisphere), as determined by anatomic MRI at approximately 13 weeks post irradiation. While 
time-to-onset of necrosis following 45-Gy irradiation in one fraction occurs much later than with 
60/50-Gy irradiation, the rates of injury progression following onset are similar. 
Neuropathological Grading System in the Murine Model of Radiation Necrosis.    
 Histologic changes are shown in control and irradiated mice (Figs 3,4).  Changes include 
50 
 
microhemorrhages, edema, vascular changes ranging from increased numbers of delicate 
telangiectatic vessels to fibrinoid necrosis and hyalinization, development of foamy macrophages, 
infiltration of polymorphonuclear leukocytes, astrocytosis, and loss of tissue elements ranging 
from neuronal loss to frank involvement of all tissue elements with microcavitation.  The 
severity of histologic changes was independently scored by three individuals, including a clinical 
neuropathologist (RES), in blinded fashion using a semi-quantitative, 0 to 3 grading system.  
Figure 3 shows the typical changes characteristic of radiation necrosis in the weeks following 
irradiation of the murine brains at both low and high magnifications.  Grade 0 was assigned to no 
histologic changes (Figure 3 A-B). Grade 1 included mild histological changes associated with 
radiation injury, including early events such as micro-hemorrhages accompanied by increased 
numbers of telangiectatic vessels (Figure 3 C-D).  Grade 2 injuries (Figure 3E-F), were 
characterized by moderate histologic changes, including changes seen in Grade 1 with addition 
of vascular hyalinization, astrocytosis and tissue loss. Grade 3 injuries (Figure 3 G-H) resembled 
those of Grade 2 but were more severe, often including tissue loss with extension to areas of grey 
matter.  Grade 3 injuries also more frequently featured fibrinoid vascular necrosis.  This grading 
system was tested independently by 4 researchers (non-pathologists), with substantial agreement 
with the neuropathologist. 
 The most severely involved animals showed hyalinized vessels and fibrinoid vascular 
necrosis (Figure 5B), and extensive fibrin deposition, highlighted by PTAH staining (blue 
regions; Figure 4G) and trichrome staining (red regions; Figure 4H). Collagen surrounding the 
vessel walls was also visualized with trichrome staining (blue material, Figure 4H).  These 
vascular changes were accompanied by macrophages clustered in damaged areas of necrosis and 
a few cells that showed radiation-induced atypia (Figure 4D). Edema formed in the center of the 
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damaged regions of brains, with decreased neuronal/glial cell density and a paucity of blood 
vessels and parenchymal structures. Degenerating neurons were characterized by loss of 
cytoplasm and condensed pyknotic nuclei  (Figure 4F).  
 Tissue damage was noted as early as 3 weeks post radiation in animals that received a 
single fraction of 60-Gy of radiation, and slightly later (4 weeks) in mice that received a single 
dose of 50-Gy of radiation. By histologic examination, no specific changes were noted at earlier 
post-irradiation time points. At later time points, areas with more severe hemorrhage (Figure 4B), 
foamy macrophages (Figure 4C), parenchymal necrosis (Figure 4F), and tissue loss (Figure 4B, 
C, and G) were observed.   
Histological scores for radiation necrosis correlate with MR-derived necrotic volumes 
For each graded histology slide, the MR-derived necrotic volume was calculated from the 
contrast-enhanced T1-weighted image for a single slice, covering the same anatomic features as 
the histological slide. The average MR-derived necrotic volumes vs. histological scores are 
plotted in Figure 5A. The two measures are highly correlated (correlation coefficient = 0.948, 
with p<0.0001) and the differences among the four cohorts (n=30, 37, 27, and 53 for Grade 0, 1, 
2, and 3, respectively) are all statistically significant (p<0.0001). Further, the correlation between 
histological score and time post irradiation is displayed in Figure 5B. The differences among the 
three cohorts (n=17, 15, and 20 for 4, 8, and 13 weeks following 50/60-Gy of radiation) are all 
statistically significant (p<0.0001). These strong correlations help to provide validation for the 
MR results and demonstrates that the histologic grading system is a useful tool for the 
classification of the severity of radiation necrosis.      
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Discussion 
Herein, we describe the development and optimization of a mouse model of late onset radiation 
necrosis. With the aid of a customized, stereotactic head-holder, well-defined doses of Gamma 
Knife radiation can be accurately and reproducibly delivered hemispherically in mouse brain. An 
optimized mouse model of radiation necrosis incorporates several important characteristics, 
including: i) consistent induction of late time-to-onset necrosis following irradiation; ii) 
characteristic MR imaging changes that allow clear identification of necrotic regions; iii) tissue 
injury whose histology accurately matches that seen in tissue from patients with confirmed 
radiation necrosis; iv) progression of necrosis occurs over a reasonable period of time, thereby 
enabling longitudinal imaging studies to characterize the onset and development of necrosis and 
its response to therapeutic interventions. Herein, the initiation and progression of necrosis in 
irradiated mice subjected to different radiation doses and fractionation schedules (60/50/45-Gy in 
a single fraction and 60-Gy in three fractions) were compared.  
As shown in Figure 2, the onset and progression of RN for mice receiving either 60-Gy or 50-Gy 
are similar, while time-to-onset of necrosis following single-fraction, 45-Gy irradiation occurs 
much later than with higher doses. The radiation dose-response relationship can be represented 
graphically by a curve that maps the biologic effects observed in relation to the radiation dose 
received. A variety of different linear and non-linear models, some including a threshold 
radiation dose for initiating tissue damage, have been proposed [23]. The sigmoid, threshold 
curve of radiation dose-response is commonly employed in radiotherapy to demonstrate high-
dose cellular response. Treating radiation-induce injury has been described as shifting this 
sigmoid curve [122]. In terms of the development of RN, a decrease of radiation dose from 50-
Gy to 45-Gy causes a much more dramatic difference than a decrease from 60-Gy to 50-Gy, 
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suggesting that 50-Gy is in the rapidly changing part of the sigmoid curve. As a result, 50-Gy is 
an appropriate radiation dose schedule for testing the efficacy of therapeutic inventions of RN. 
50-Gy also provides an appropriate observation window (from-4-to-13 weeks post irradiation) 
for the development of late-onset necrosis, with evident weekly change in the volume of the 
necrotic region. Although this dose is substantially higher than a clinical-dose schedule, the 
resulting radiation necrosis is histologically similar to that induced in patients, suggesting that all 
the positive results of this model of necrosis can be readily translated. 
Our robust mouse model recapitulates significant features of radiation necrosis that occur in 
response to a number of clinical treatment paradigms. These features include the delayed-onset 
of radiation changes and well-described histologic changes. A histologic grading system was 
developed to allow us to assess the severity of the radiation-induced changes in a systemic 
fashion. Such a semi-quantitative grading system may be employed to assess the effects of 
radiation sensitizers or protective agents. These studies will not only test the efficacy of various 
treatment paradigms, but will allow the mechanisms involved in the onset and progression of 
delayed radiation necrosis and its response to therapeutic interventions to be studied. 
Conclusion 
By employing the Leksell Gamma Knife Perfexion to stereotactically deliver radiation to one 
hemisphere of the mouse brain, we have developed a novel murine model of late time-to-onset 
radiation necrosis. The animal model can be used to reproducibly study radiation necrosis that 
simulates changes noted in radiation necrosis in the brain. A four-level histologic scoring system 
was developed to grade the severity of radiation necrosis. The onset and progression of RN in 
this model can be quantitatively characterized by both preclinical MRI and histology. This mouse 
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model of RN can, thus, serve as a robust platform for a variety of studies, including imaging 
biomarkers for differentiation of RN from recurrent tumor, mitigation and neuroprotection of 
radiation necrosis.  
 
 
Figures 
 
Figure 2.1. MRI can detect radiation necrosis in irradiated mouse brain. Representative contrast-
enhanced transaxial T1-weighted spin-echo images of irradiated mice at 1, 4, 8, and 13 weeks 
following a single 50-Gy (50% isodose) of radiation. Slices are chosen to display the same 
anatomic region of the brain at all four time points. 
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Figure 2.2. MRI-derived necrotic volumes, mean ± SD (n = 15), vs. time post-irradiation for 
mice irradiated hemispherically with different dose schedules: 60-Gy in 1 fraction (red), 60-Gy 
in 3 fractions (green), 50-Gy in 1 fraction (black) and 45-Gy in 1 fraction (blue).  
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Figure 2.3. Representative pictures of irradiation damage of each grade. Panels A, C, E, and G 
are shown at 1x, with arrows indicating the irradiated hemisphere of the brain; Panels B, D, F, 
and H are shown at 100x magnification, thereby revealing more detail in the irradiated areas. 
Panels A and B (Grade 0): The irradiated brain shows no pathological changes. Panels C and D 
(Grade 1) in which the earliest histological events noted were micro-hemorrhages accompanied 
by increased numbers of telangiectatic vessels. (arrow). In grade 2 damage (Panels E and F), 
there were typically larger parenchymal hemorrhages (arrow), neuronal necrosis and tissue loss 
(*), with approximately one-half to two-thirds of the left hemisphere involved. Grade 3 damage 
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(Panels G and H) typically involves more extensive areas, with severe tissue damage, including 
fibrinoid vascular necrosis (+) and tissue loss (**). 
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Figure 2.4.  Pathological features in post-irradiation mouse brain. A. Micro-hemorrhages and 
dilated vessels (arrows, 20X).   B. Hemorrhages (arrow) and fibrinoid vascular necrosis (+) 
(H&E staining, 20X).   C. Activated microphages surrounding damaged tissues (arrow, 20x).   D. 
Neuronal necrosis (arrows, 60X).  E. Edema and hemorrhage (*, 20X).   F. Cellular atypia (*, 
60X).  G. PTAH staining shows fibrinoid vascular necrosis in dark blue (arrows, 20X).  H. 
Trichrome staining demonstrates fibrinoid vascular necrosis (red, arrows) and collagen in light 
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blue ( ^)(20X).  
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Figure 2.5. A. Correlation between MR-derived necrotic volumes and histological scores. MR-
derived volumes, mean ± SD (n = 30, 37, 27, and 53 for Grade 0, 1, 2, and 3, respectively), of 
radiation necrosis vs. histological score for all the irradiated mice, regardless of radiation dosing 
and treatment schedules.  B1. Correlation between histological scores and time post irradiation. 
Box-and-whisker plot of the histological scores for mice receiving 50/60-Gy of radiation, at 4, 8, 
and 13 weeks post irradiation. The 25th-75th percentiles are blocked by the box, and the 
whiskers identify the standard deviation. 
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Introduction 
Radiation is a key component in the treatment of both benign and malignant central nervous 
system tumors, including gliomas, metastases, meningiomas, schwanomas, pituitary adenomas, 
and other less common neoplasms. Multiple radiation-treatment schemes have been developed to 
treat various neoplasms in the brain. These treatment protocols utilize a variety of different 
fractionation and conformational schemes designed to deliver focused radiation to regions in the 
brain to maximize control of tumor growth and minimize deleterious effects on normal brain 
tissue. Outcomes of these clinical protocols may be complicated by radiation effects on non-
neoplastic tissue, resulting in a spectrum of phenotypes, ranging from minimal change with no 
observable clinical symptoms, to delayed radiation necrosis with severe neurological sequelae. 
The delayed effects from radiation may produce cerebral edema and necrosis of normal brain 
parenchyma, resulting in untoward neurologic effects that are difficult to differentiate from 
recurrent tumor growth. 
Radiation necrosis, a delayed radiation neurotoxicity that can occur after radiation treatment of 
the CNS, can develop between 3 months and 10 years after radiotherapy, with most cases 
occurring in the first two years [1]. Necrosis following radiation is not uncommon, occurring in 
3-24% of patients receiving focal irradiation [1]. The incidence may be threefold higher with 
concurrent chemotherapy [3, 112]. Currently, only limited options for therapeutic intervention 
are available for patients with symptomatic radiation necrosis. Surgical resection of necrotic 
tissue is often not possible due to the location of the necrosis in eloquent regions of the brain. 
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Prolonged treatment with corticosteroids is often employed [55], but is complicated by 
cushingoid side-effects, including weight gain, myopathy, immunosuppression, psychiatric 
disturbances, and occasionally arthritic sequelae, such as avascular necrosis affecting the 
shoulders and hips [56]. Hyperbaric oxygen treatment has also been considered as a therapeutic 
modality [57, 59]. However, it is cumbersome to deliver, expensive, and available in few medical 
centers. Its benefit has only been shown in a relatively small number of cases [58]. 
Two models of the pathogenesis of radiation necrosis have been proposed. These models involve 
radiation-induced injury to vasculature, radiation-induced injury to glial cells (apoptosis), or a 
combination thereof [123]. In particular, radiation necrosis has been associated with breakdown 
of the blood brain barrier, leading to increased vascular permeability and elevated levels of 
vascular endothelial growth factor (VEGF) [1, 5]. Elevated VEGF levels can, in turn, damage 
vascular endothelial cells and, together with subsequent narrowing of vessels due to fibrosis, can 
result in edema and necrosis [124]. 
Bevacizumab, a humanized monoclonal antibody against VEGF, was first approved by the FDA 
in 2004 for use in treating metastatic colorectal cancer. Since then, it has also been approved for 
the treatment of non-small-cell lung cancer, metastatic breast cancer, and recurrent glioblastoma 
[125]. Bevacizumab has been reported to normalize the vasculature, thereby enhancing the 
efficient delivery of drugs [126, 127]. There is clinical evidence that bevacizumab substantially 
decreases the effects of radiation necrosis [61-64, 128]. A recent randomized double-blind study 
of bevacizumab therapy for the patients with radiation necrosis [64] provided evidence of its 
efficacy in mitigating radiation necrosis. These studies relied on MR imaging, and, in particular, 
T1 post-gadolinium enhancement to characterize radiation necrosis, which is complicated by the 
presence of recurrent tumor. Also, because it is generally not possible to correlate time-course 
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MR observations with histologic findings in patients, these human studies lack information 
regarding the mechanisms of action of bevacizumab. Thus, further studies are needed to validate 
the effects and mechanisms of bevacizumab in the treatment of radiation necrosis. 
We have recently developed a mouse model of delayed time-to-onset injury [101] that 
recapitulates the histologic features observed in patients suffering from CNS radiation necrosis. 
This model provides a platform for studies aimed at developing methods to identify/detect, 
monitor, protect against, and mitigate radiation necrosis, and distinguish it from tumor regrowth. 
In the work reported herein, this model is employed to validate the efficacy of both murine and 
humanized anti-VEGF-A monoclonal antibodies as mitigators of radiation necrosis following 
high-dose radiation treatment. 
Materials and Methods 
Animals 
All studies were performed in accordance with the guidelines of the IACUC and in accordance 
with protocols approved by the Washington University Division of Comparative Medicine that 
met or exceeded American Association for the Accreditation of Laboratory Animal Care 
standards. Female Balb/c mice were used for the study and observed daily and weighed weekly 
to ensure that interventions were well tolerated. 
Irradiation and Treatment 
Mice were irradiated with the Leksell Gamma Knife® Perfexion™ (Elekta; Stockholm, Sweden; 
http://www.elekta.com/), a state-of-the-art unit used for stereotactic irradiation of patients with 
malignant brain tumors. Mice were supported on a specially designed platform mounted to the 
stereotactic frame that attaches to the treatment couch of the Gamma Knife. Mice were 
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anesthetized with a mixture of ketamine (25 mg/kg), acepromazine (5 mg/kg) and xylazine (5 
mg/kg), injected intraperitoneally 5 min before the start of irradiation. 35 female Balb/c mice 
were irradiated with either 60 Gy or 50 Gy, as described below, and the resulting brain 
parenchymal changes were characterized by both MRI and histology. 
VEGF inhibitory monoclonal antibody 
Bevacizumab (Genentech/Roche) is a humanized mAb (monoclonal antibody) that inhibits 
VEGF-A. Anti-VEGF antibody B20-4.1.1, heretofore referred to as B20-4.1.1, is a cross-species 
reactive, function-blocking mAb targeting both human and murine VEGF-A. 
Experimental Outline 
As part of the overall study, two different sets of experiments, designated as “A” and “B” were 
performed. In experiment “A”, two cohorts of mice (n=10 each) received a single 50-Gy dose 
(50% isodose) of Gamma Knife radiation. At this dose, the onset of radiation necrosis typically 
occurs approximately 4 weeks post-irradiation. Mouse cohort #1 was an irradiated, non-antibody 
(Ab)-treated, control group; cohort #2 received B20-4.1.1 (10 mg/kg), twice weekly, from 4-to-
13 weeks post-irradiation. In experiment “B”, three cohorts of mice received a single fraction of 
60-Gy radiation (50% isodose). At this dose, the onset of radiation necrosis typically occurs ~3 
weeks post-irradiation. Mouse cohort #1 (n=5) was an irradiated, non-Ab-treated antibody, 
control group; cohort #2 (n=5) received B20-4.1.1 (10 mg/kg), twice weekly, from 3-to-10 
weeks post-irradiation; cohort #3 (n=5) received bevacizumab (10 mg/kg, twice weekly) from 3-
to-10 weeks post-irradiation. Antibodies were administered intraperitoneally. 
MR Imaging 
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Images were collected in an Agilent/Varian (Santa Clara, CA) 4.7-T small-animal MR scanner 
equipped with a DirectDriveTM console. The scanner is built around an Oxford Instruments 
(Oxford, United Kingdom) 33-cm, clear-bore magnet equipped with 21-cm inner diameter, 
actively shielded Agilent/Magnex gradient coils (maximum gradient, 28 G/cm; rise time 
approximately 200 ms) and Oy International Electric Company (IEC; Helsinki, Finland) model 
A-240 amplifiers (300 V and 300 A). 
MRI data were collected using an actively decoupled coil pair: 1.5-cm outer diameter surface 
coil (receive) and a 9-cm inner diameter Helmholtz coil (transmit). Before the imaging 
experiments, mice were anesthetized with isoflurane/O2 (3% [vol/vol]) and maintained on 
isoflurane/O2 (1% [vol/vol]) throughout the experiments. Mice were restrained in a laboratory-
constructed Teflon head holder with ear bars and a tooth bar. To maintain the body temperature 
of the mice at approximately 37°, mice placed on a water pad circulating warm water. Mice were 
injected intraperitoneally with 0.5 mL Omniscan (gadodiamide; GE Healthcare, Princeton, NJ) 
contrast agent, diluted 1:10 in sterile saline. 
Non-Ab-treated mice treated with 50 Gy of radiation were imaged 4, 8, and 13 weeks post-
irradiation. Ab-treated mice that had received 50 Gy of radiation were imaged 4, 5, 7, 9, 11, and 
13 weeks post-irradiation. Mice that had received 60 Gy of radiation were imaged weekly from 
3-to-10 weeks post-irradiation (non-Ab-treated mice were not imaged at week 9). Multislice, T2-
weighted, spin-echo transaxial images were collected beginning ~3 minutes following 
gadodiamide administration with the following parameters: time to repetition [TR] = 1.5 s, time 
to echo [TE] = 0.05 s, field of view [FOV] = 1.5 x 1.5 cm2, slice thickness = 0.5 mm, 21 slices to 
cover the whole brain; total acquisition time = 12 minutes. Multislice, T1-weighted, spin-echo 
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transaxial images were then collected over 5 minutes with the following parameters: TR = 0.65 s, 
TE = 0.02 s, FOV = 1.5 x 1.5 cm2, slice thickness = 0.5 mm, 21 slices to cover the whole brain. 
Histology 
Immediately after the last MR imaging session (13 weeks post-irradiation for mice receiving 50-
Gy irradiation, 10 weeks post-irradiation for mice receiving 60-Gy irradiation), all the mice were 
perfused intracardially with 0.1 M Phosphate-buffered saline and formalin. The heads were then 
dissected and immersed in formalin for 24 hrs. All the brains were removed from skulls and 
embedded in paraffin. A single, 8-micron-thick coronal tissue section was taken from each brain 
near the radiation center and stained with hematoxylin and eosin (H&E) according to standard 
protocols. Histologic comparison of tissue sections was facilitated by the accurate targeting of 
radiation, ensuring that all histologic slices reflected the same anatomic features. 
Statistical Analysis 
For experiment “A”, Laird and Ware’s growth curve method [129] was used to compare the 
differences in the rates of progression of radiation necrosis, since the Ab-treated and non-Ab-
treated irradiated cohorts were imaged at different time points. For experiment “B”, in addition 
to the overall rates of progression, two-way ANOVA for repeated measurement data was also 
used to compare the MRI-derived necrotic volumes between Ab-treated and non-Ab-treated 
irradiated cohorts, followed by ad hoc multiple comparisons for differences at specific time 
points. All the tests were two-sided and a p-value of 0.05 or less was taken to indicate statistical 
significance. The statistical analysis was performed using SAS 9.3 (SAS Institutes, Cary, NC).  
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Results 
MRI detects radiation necrosis as image hyperintensity in T2-weighted images 
Representative T2-weighted spin-echo images of control, bevacizumab-treated, and B20-4.1.1-
treated mice, covering the same anatomic region of the brain and collected at 3, 6, and 10 weeks 
following a single 60 Gy dose of radiation, are shown in Figure 1. Hyperintense areas in these 
images correspond with region of radiation necrosis in the brain. Significant hyperintense 
regions are clearly seen in non-Ab-treated, control mice at 6 weeks post irradiation and these 
regions expand significantly in extent by 10 weeks. The images of mice treated with B20-4.1.1 
show minimal hyperintensity, even at 10 weeks post irradiation, while the images of 
bevacizumab-treated mice describe an intermediate situation, showing no hyperintense regions at 
6 weeks but small such regions at 10 weeks post irradiation. 
Necrosis volumes can be measured quantitatively from MR images 
For each set of T2-weighted spin-echo images, regions of interest were drawn around the entire 
brain in several contiguous image slices, chosen to include the entire hyperintense region. Each 
brain was divided along the midline into left (irradiated) and right (non-irradiated) hemispheres. 
The image intensity for each individual pixel in the left hemisphere was normalized by the 
average of the 25 pixels (5 x 5 square) including and immediately surrounding its mirror-image 
pixel in the right hemisphere, and histograms of normalized intensity for the irradiated 
hemisphere were constructed, as shown in Figure 2. The same analysis was performed on a 
cohort (n=10) of non-irradiated mice. The histogram of average intensity distribution for non-
irradiated subjects, shown in Figure 2A, is symmetric; 99% of the pixels are distributed in the 
intensity range 0.6 – 1.4 about a normalized mean of 1.0. Therefore, an intensity threshold of 1.4 
was chosen as the cutoff for normal brain tissue. For images of irradiated mice with/without 
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treatment at different weeks post-irradiation, the number of pixels exceeding this threshold 
serves to measure the necrotic volume at each time point.  Figure 2B shows image-pixel intensity 
histograms for B20-4.1.1- and bevacizumab-treated mice at 6 and 10 weeks following a single 
60-Gy dose of radiation. The rates of progression of radiation necrosis over the designated time 
period can be derived from the slopes of least-squares fits of # pixels vs. time over the designated 
period.  
Anti-VEGF antibodies slow the progression of radiation necrosis in irradiated brain tissue 
Figure 3 shows the progression of the mean volumes of MRI-derived necrotic regions for non-
Ab-treated and B20-4.1.1-treated mice in Experiment A, in which all the mice received a single, 
50-Gy dose of radiation. There was almost no progression of radiation necrosis in the B20-4.1.1-
treated cohort (p < 0.0001) compared to non-AB-treated control, indicating a significant 
mitigative effect due to the treatment. 
Figure 4A shows the progression of the mean volumes of necrotic region for non-Ab-treated, 
bevacizumab-treated, and B20-4.1.1-treated cohorts in Experiment B, in which all the mice 
received a single 60 Gy dose of radiation. The overall slope of the progression curve for B20-
4.1.1-treated mice is slightly negative, demonstrating the mitigative effect of B20-4.1.1 where 
the treated cohort had a greatly diminished volume of necrosis at week 10 post-irradiation 
compared to non-Ab-treated controls (p < 0.0001, week 10). Bevacizumab also slows the overall 
rate of progression (p<0.0001, week 10). Considering the initial 3-7 week period post-irradiation, 
bevacizumab has the same mitigative effect as B20-4.1.1 (p = 0.8, week 7). However, for the 
latter 7-10 week period, radiation-induced necrosis developed at a higher rate than in the B20-
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4.1.1-treated cohort (p<0.0001, week 10), indicating that the mitigative effect of bevacizumab 
was weaker than B20-4.1.1 in the late period following the initiation of treatment. 
These effects are evident in Figure 4B, in which the rates of progression of radiation necrosis for 
the three cohorts are plotted. The progression rate for the B20-4.1.1-treated cohort was 
substantially reduced relative to the non-Ab-treated cohort over both the 3-7 week (p<0.0001) 
and 7-10 week periods (p=0.0002) post-irradiation. While bevacizumab treatment slowed the 
rate of progression relative to the non-Ab-treated cohort during the initial 3-7 week period 
(p<0.0001), its effect was lost over the latter 7-10 week period (p=0.2). It is apparent that in 
mice, B20-4.1.1 was a more potent mitigator of radiation necrosis compared to bevacizumab. 
Histology reveals that anti-VEGF antibodies mitigate radiation necrosis in irradiated brain 
tissue 
Figure 5(A) shows representative 2x (top), 10x (middle) H&E histologic images and 
corresponding T2W MR images (bottom) for non-Ab-treated, bevacizumab -treated, and B20-
4.1.1-treated mice at 10 weeks following a single, 60-Gy dose of radiation. Corresponding 
histologic images and T2-weighted images of control and B20-4.1.1 –treated mice following a 
single, 50-Gy fraction of radiation are shown in Figure 5(B). The irradiated hemispheres of the 
control mice demonstrated many of the classic histologic features of radiation necrosis, including 
fibrinoid vascular necrosis (black arrow), vascular telangiectasia (yellow arrows), hemorrhage 
(red arrow), and loss of neurons and edema (blue arrows) [4]. In contrast, the irradiated 
hemisphere of the bevacizumab-treated mouse showed only modest tissue damage and the 
irradiated hemisphere of the B20-4.1.1-treated mouse displayed no visible tissue damage. These 
histologic findings support the MR data shown in Figs. 3 and 4, demonstrating a significant 
mitigative effect of anti-VEGF-A therapy. 
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Discussion 
Surgery, chemotherapy, and/or radiation are modalities utilized in treatment protocols for patients 
with brain neoplasms. The risk of late-onset radiation necrosis significantly limits the efficiency 
of such treatment. The identification of agents that mitigate the delayed effects of radiation-
induced changes on normal tissue, while not reducing the therapeutic efficacy of radiation on 
tumor tissue, could significantly increase the effectiveness of radiation paradigms. Currently, the 
clinical therapeutic options for treating radiation necrosis are limited.  
It has been suggested that radiation necrosis results from local tissue injury characterized by 
disruption of the blood-brain barrier and consequent tissue edema. Endothelial cell death, which 
results in breakdown of the blood-brain barrier, edema, and hypoxia and enhanced expression of 
VEGF has been described as an important step in the development of radiation necrosis [5]. The 
mitigative potential of anti-VEGF therapy using Bevacizumab in the treatment of radiation 
necrosis has been shown in several retrospective human studies and a recent prospective human 
study in a small number of patients [61-64], though these studies lacked statistical power. MRI 
monitoring of the onset and progression of radiation necrosis, in concert with Gamma Knife 
irradiation, offers an attractive strategy for validating and optimizing anti-VEGF-Ab therapy. We 
have established an animal model that faithfully reproduces the histology of radiation necrosis 
observed in patients. Herein, we demonstrate that anti-VEGF antibodies can delay the onset of 
radiation necrosis and believe that the results of mitigation studies in the mouse may be 
immediately and readily translatable. 
In this study, the onset and progression of radiation necrosis in mouse brain were characterized 
by the volume of hyperintense regions on T2-weighted images. Characterization employing 
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contrast-enhanced T1-weighted images yielded essentially equivalent findings (data not shown). 
The greatly reduced progression of radiation necrosis in treated mice, as measured longitudinally 
by in vivo MR imaging, and the much lighter tissue damage observed in H&E-stained tissue 
sections for bevacizumab- and B20-4.1.1-treated mice, demonstrated the efficacy of anti-VEGF-
A therapy. B20-4.1.1 has a better mitigative effect than bevacizumab in the mouse model of 
radiation necrosis. The mitigative effects of bevacizumab disappeared approximately 4 weeks 
after the start of treatment (Fig. 4). This may be due to an anti-idiotypic immunogenic response 
[130-132], whereby murine antibodies directed against the antigen specific part of bevacizumab 
are produced, thereby inhibiting its binding to mouse VEGF. The greater therapeutic efficacy of 
B20-4.1.1 is likely due to its higher affinity for mouse VEGF-A [133]. 
Although the results of the present study demonstrate that bevacizumab and B20-4.1.1 can 
significantly reduce the progression of radiation necrosis, the mechanism of the mitigative effect 
of these VEGF inhibitors remains undetermined and requires further investigation. Future studies 
that address mechanism of action will include Dynamic Contrast-Enhanced MRI, an imaging 
method for quantitatively measuring vascular permeability [27, 79] and specific histological 
stains targeting permeability, such as Evans Blue [134]. 
Outstanding questions also remain regarding the ideal dosing schemes and the treatment periods 
for anti-VEGF-Ab therapy. Multiple dosing schemes, ranging from 5 mg/kg to 10 mg/kg have 
been reported in the treatments of tumor and radiation necrosis in both human [61, 64] and 
animal studies [135]. Typically, bevacizumab, with a half-life of approximately 20 days in 
humans, is administered once every 2 or 3 weeks in patients [61, 64, 136], and once or twice 
weekly in mice [60, 135]. For our mitigation study, a high-end dosing scheme (10 mg/kg, twice 
weekly) was chosen and demonstrated promising mitigative effects on radiation necrosis in mice. 
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Nonetheless, minimizing the dose required to effective control the progression of necrosis will 
reduce patient costs and potential side effects, thereby improving the likelihood of effective 
clinical translation. Studies measuring the effects of using lower doses of B20-4.1.1 in our mouse 
model are ongoing in our lab. Also, in the current studies, irradiated mice were treated with 
bevacizumab or B20-4.1.1 for 7 or 8 weeks, beginning with the first radiographic sign of 
radiation necrosis. However, the mitigative effectiveness found upon initiating the treatment 
earlier (e.g., immediately following irradiation) or stopping the treatment after a fixed period of 
time (e.g., 4 weeks) remain to be investigated. 
Conclusion 
The data in this study demonstrate a significant mitigative effect of both bevacizumab and 
B20-4.1.1 in a mouse model of radiation necrosis. By reducing the development of necrosis 
following irradiation, anti-VEGF-Ab therapy may overcome the deleterious effects of focal 
irradiation to effectively treat lesions with fewer side effects. Efforts to optimize dosing schemes 
and treatment periods and elucidate the mechanisms of mitigative effect of bevacizumab and 
B20-4.1.1 in the treatment of radiation necrosis in this mouse model are ongoing. 
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Complementary data 
DCE MR imaging 
For DCE MR imaging, a 2D T1-weighted fast spoiled gradient-echo sequence was used to obtain 
dynamic sets of 3 slices with a slice thickness of 1.0 mm, field of view of 15 x 15 mm2, matrix of 
64 x 64, TR = 20 ms, TE = 3.10 ms, and Flip angle = 20 degree. 200 sets of images were 
collected continuously with about 5 s for each set. 0.17 mL Omniscan (gadodiamide; GE 
Healthcare, Princeton, NJ) contrast agent was injected via tail vein within 1 s at the 10th set of 
images. 
 
Anti-VEGF antibodies decrease the vasculature permeability in the necrotic region 
Figure 3.6 compares the endothelial transfer constant (Ktrans) maps for control (left) and B20-
4.1.1-treated (right) mice at 13 weeks post irradiation. Large high Ktrans regions associated to 
radiation-induced BBB breakdown are indentified in the irradiated hemispheres of control mice. 
In contrast, the Ktrans values are close to zero in both irradiated and contralateral hemispheres of 
B20-4.1.1-treated mice, indicating that B20-4.1.1 significantly decreased the permeability of 
BBB in irradiated mouse brain.  
The Ktrans maps for the same animal before and after one-time B20-4.1.1 treatment are shown in 
Figure 3.7. It is evident that the Ktrans values in the irradiated hemisphere decreased dramatically 
after a single B20-4.1.1 treatment. Further, the hyperintense regions on T2-weighted images 
associated with necrotic regions is larger at 7 weeks post irradiation than 6 weeks, indicating that 
a single treatment cannot mitigate the progression of necrosis.   
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Figures 
 
Figure 3.1. MRI can detect radiation necrosis in irradiated brain. Representative, transaxial, T2-
weighted spin-echo images acquired longitudinally from non-Ab-treated, bevacizumab-treated, 
and B20-4.1.1-treated mice at 3 (top), 6 (middle) and 10 weeks (bottom) following a single 60 
Gy at (50% isodose) of radiation. Slices are chosen to display the same anatomic region of the 
brain at all three time points. 
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Figure 3.2. Histogram analysis enables quantitative MRI measurement of necrotic volume. (A) 
Image-pixel intensity histograms for the same non-Ab-treated mouse at 6 and 10 weeks 
following a single 60 Gy of radiation (red, blue) and average intensity histogram for 10 non-
irradiated non-Ab-treated mice (black). The intensity cutoff used to define hyperintense pixels, 
corresponding to necrotic tissue, is indicated by the labeled arrow at a normalized intensity of 1.4. 
(B) Image-pixel intensity histograms for the same B20-4.1.1-treated (red) and bevacizumab-
treated (blue) mice at 6 (dash line) and 10 (solid line) weeks following a single 60-Gy dose of 
radiation. 
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Figure 3.3. MRI-derived necrotic volumes in mice irradiated hemispherically with a single 50-
Gy dose of GK radiation. MRI-defined volumes, mean ± SD (n = 10), of radiation necrosis vs. 
time post-irradiation for non-Ab-treated and B20-4.1.1-treated mice; all the mice received a 
single 50-Gy of radiation (50% isodose). Compared to non-Ab-treated control, almost no 
progression of radiation necrosis in the B20-4.1.1-treated cohort (p<0.0001) was observed. 
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Figure 3.4. MRI-derived necrotic volumes in mice irradiated hemispherically with a single 60-
Gy dose of GK radiation. (A) MRI-defined volumes, mean ± SD (n = 5), of radiation necrosis vs. 
time post-irradiation for non-Ab-treated, bevacizumab -treated, and B20-4.1.1-treated mice; all 
the mice received a single 60-Gy of radiation (50% isodose). At the 0.0001 level, MR-derived 
necrotic volumes for both treated cohorts were significantly smaller than the non-Ab-treated 
cohort at week 6, 7, 8, and 10 post-irradiation. The differences in the volumes between 
bevacizumab-treated and B20-4.1.1-treated cohorts was  significant at week 10 post-irradiation 
(p<0.0001), but not significant at week 7 post-irradiation (p = 0.8), indicating that the mitigative 
effect of bevacizumab was weaker than B20-4.1.1 in the late period following the initiation of 
treatment. (B) MRI-defined volumetric rate of radiation necrosis progression, mean ± SD (n = 5), 
derived from the slope of the curves in the left panel, for the 3-7 and 7-10 week periods. The 
progression rates for both treated cohorts were significantly reduced relative to the non-Ab-
treated cohort over the 3-7 week period (P<0.0001) post irradiation.  For the 7-10 week period 
post irradiation, only B20-4.1.1 treatment slowed the rate of progression relative to the control 
(p=0.0002). 
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Figure 3.5. H&E-stained sections display characteristic histologic features of radiation necrosis 
and demonstrate mitigation by anti-VEGF Ab. (A) Representative 2x (top) and 10x (middle) 
H&E histology slices chosen near the radiation isocenter, and corresponding T2W images 
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(bottom) for non-Ab-treated, bevacizumab-treated, and B20-4.1.1-treated mice at 10 weeks 
following a single 60-Gy fraction of radiation. (B) Representative 2x (top) and 10x (middle) 
H&E histology slices, and corresponding T2W images (bottom) for one control and two B20-
4.1.1-treated mice at 13 weeks following a single 50-Gy fraction of radiation. The irradiated 
hemispheres of the control mice show many of the histologic features that are characteristic of 
radiation necrosis, including fibrinoid vascular necrosis (black arrow), vascular telangiectasia 
(yellow arrows), hemorrhage (red arrow), loss of neurons and edema (blue arrows). In addition, 
the tissue injury observed on the histology slices are highly correlated with the hyperintense 
regions on T2W images. 
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Figure 3.6. The Ktrans maps. (Left) different columns represent three contiguous slices from the 
same animal, and different rows represent three control mice; (Right) different columns represent 
three contiguous slices from the same animal, and different rows represent three B20-4.1.1-
treated mice. 
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Figure 3.7. The Ktrans maps (A) and corresponding T2-weighted images (B) for the same mouse, 
before (top) and after (bottom) one single B20-4.1.1 treatment. Different columns represent three 
contiguous slices. 
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Introduction 
Radiation necrosis (RN) is a major complication of radiotherapy [1] that often limits radiation 
dose. The incidence of reported RN ranges from 3-24% of patients following focal irradiation 
[56, 115, 137, 138] and may be up to threefold higher with concurrent chemotherapy [3, 112].  A 
number of treatment options for RN are available [55-58, 62-64], however each therapy has 
limitations and introduces potential complications for patients. Current interventions have 
limited success in mitigating RN. 
Proposed mechanisms leading to RN in the brain include radiation-induced injury to vasculature 
and apoptosis [116]. In particular, RN has been associated with acute apoptosis of 
oligodendroglial precursor cells that results in: (i) loss of mature oligodendrocytes, (ii) 
demyelination and white-matter necrosis [139], and (iii) damaged astrocytes that result in 
breakdown of the blood brain barrier (BBB) [140, 141]. BBB breakdown is associated with 
elevated levels of vascular endothelial growth factor (VEGF) and, together with subsequent 
narrowing of vessels due to fibrosis, can result in edema and necrosis [5]. Inhibiting the 
apoptotic process of glial cells may prevent or ameliorate the development of radiation necrosis. 
Others and we have studied neuroprotection by GSK-3β inhibitors, which increase neuronal cell 
viability [26-29, 44]. GSK-3β is a multifunctional serine/threonine kinase originally identified as 
a regulator of glycogen metabolism [142]. GSK-3β is widely expressed in most tissues, however, 
it is expressed abundantly in brain and especially in neurons, due to its vital role in neuronal 
signalling  [143].  
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GSK-3β has been shown to induce apoptosis in response to a wide variety of conditions [144-
146] including irradiation[147]. In cell culture studies, apoptosis was either attenuated or 
prevented by inhibiting GSK-3β in primary [148] and hippocampal (HT-22) neurons,[149]. 
GSK-3β inhibition has been demonstrated to enhance survival of irradiated endothelial cells due 
to attenuated apoptosis and to protect cells in vivo from radiation-induced apoptosis  [150]. 
GSK-3β inhibitors are utilized for the treatment of various diseases [151-153], with ongoing 
development of new GSK-3β inhibitors that are in various phases of clinical trials[153]. 
Accordingly, GSK-3β inhibition represents a potential therapeutic approach in the treatment of 
radiation necrosis. 
A novel animal model of radiation necrosis has been developed in our lab [101] that accurately 
recapitulates the classic histologic features of radiation necrosis observed clinically and provides 
a robust platform to test the efficacy of neuroprotective drugs. This model is employed herein to 
validate the neuroprotective effect of SB 415286, a specific GSK-3β inhibitor, in mouse brain 
following high-dose radiation treatment. Further, the effect of SB 415286 on the effectiveness of 
radiation therapy in tumor bearing mice is investigated. 
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Materials and Methods 
Animals 
Female Balb/c mice were used for the study and observed daily and weighed weekly to ensure 
that interventions were well tolerated. 
Irradiation and treatment 
Mice were irradiated with the Leksell Gamma Knife® Perfexion™ (Elekta; Stockholm, Sweden; 
http://www.elekta.com/), a state-of-the-art device used for stereotactic irradiation of patients with 
malignant brain tumors. Mice were supported on a specially designed platform mounted to the 
stereotactic frame that attaches to the treatment couch of the Gamma Knife (GK). Mice were 
anesthetized with a mixture of ketamine (25 mg/kg), acepromazine (5 mg/kg), and xylazine (5 
mg/kg), injected intraperitoneally 5 min before the start of irradiation. Mice were irradiated with 
a single 45-Gy fraction targeted to the left hemisphere (brain). The resulting brain parenchymal 
changes were monitored and characterized by MRI and histology. 
GSK-3β  inhibitor  
SB 415286 (GlaxoSmithKline; London, UK) is a potent and selective cell-permeable, ATP-
competitive GSK-3β inhibitor with an IC50 and a Ki of 78 and 31 nM, respectively [154]. 
Experimental 0utline 
Two different sets of experiments, designated as “A” and “B” were performed. Experiment “A” 
was designed to validate the efficacy of GSK-3β inhibition in the treatment of radiation necrosis. 
Two cohorts of mice (n=12 each) received a single 45-Gy dose (50% isodose) of GK radiation. 
At this dose, the onset of radiation necrosis typically occurs 10-12 weeks post-irradiation. Mouse 
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cohort #1 was an irradiated, DMSO-treated, control group; cohort #2 was treated with SB 
415286 (1mg/kg in DMSO) i.p. at 24 h, 12 h and 30 min prior to irradiation. 
Experiment “B” was designed to test whether GSK-3β inhibition would also have protective 
effects in tumor tissue. Orthotopic tumors were generated using DBT glioma cells, as described 
previously [155]. Post-contrast T1-weighted imaging was performed on post-implantation day 
(PID) 9 to confirm tumor implantation. Mice were randomly assigned into three cohorts: cohort 
#1 (n=10) was an untreated control group (no irradiation, no SB 415286); cohort #2 received a 
total 22.5 Gy dose (50% isodose) of GK radiation targeted to the tumor site over 3 fractions 
given at PID 10, 12 and 14 (but no SB 415286); cohort #3 received the exact same radiation 
treatment as cohort #2 but was also treated with SB 415286 (1 mg/kg), at 24 h, 6 h and 30 min 
prior to the first irradiation fraction and then 30 min prior to the subsequent irradiation fractions. 
Mice were sacrificed if/when they lost more than 20% bodyweight, suffered obvious behavioral 
detriments (such as ataxia), or had significantly large tumors as determined by MRI imaging. 
MR imaging 
Images were collected in an Agilent/Varian (Santa Clara, CA) 4.7-T small-animal MR scanner 
equipped with a DirectDrive console. The scanner is built around an Oxford Instruments (Oxford, 
United Kingdom) 33-cm, clear-bore magnet equipped with a 21-cm inner diameter, actively 
shielded Agilent/Magnex gradient coil assembly (maximum gradient, 28 G/cm; rise time 
approximately 200 ms) and Oy International Electric Company (IEC; Helsinki, Finland) model 
A-240 amplifiers (300 V and 300 A). 
Data were collected using an actively decoupled coil pair: 1.5-cm outer diameter surface coil 
(receive) and a 9-cm inner diameter Helmholtz coil (transmit). Mice were anesthetized with 
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isoflurane/O2 (3% [vol/vol]) before the imaging experiments and maintained on isoflurane/O2 (1% 
[vol/vol]) throughout the experiments. Mice were restrained in a laboratory-constructed Teflon 
head holder with ear bars and a tooth bar and were placed on a water pad with circulating warm 
water to maintain body temperature at approximately 37°C. They were injected intraperitoneally 
with 0.5 mL Omniscan (gadodiamide; GE Healthcare, Princeton, NJ) contrast agent, diluted 1:10 
in sterile saline, 15 min before being placed in the magnet. 
Mice in experiment “A” that received 45 Gy of radiation were imaged 10, 13, 16, 19 and 22 
weeks post-irradiation. For cohort #1 in experiment “B”, the untreated control group, mice were 
imaged at PID 10 and then every 3 days until they were sacrificed. For cohorts #2 and #3 of 
experiment “B”, the treated groups, mice were imaged at PID 10 (before receiving GK radiation), 
17, and then every 3 days until they were sacrificed. Multislice, T2-weighted, spin-echo 
transaxial images were obtained during the 3-15 minutes immediately following gadodiamide 
administration with the following parameters: time to repetition (TR) = 1.5 s, time to echo (TE) 
= 0.05 s, field of view (FOV) = 1.5 x 1.5 cm2, slice thickness = 0.5 mm, 21 slices to cover the 
whole brain. Multislice, T1-weighted, spin-echo transaxial images were then obtained over 5 
minutes with the following parameters: TR = 0.65 s, TE = 0.02 s, FOV = 1.5 x 1.5 cm2, slice 
thickness = 0.5 mm, 21 slices to cover the whole brain. 
Histology 
Immediately after the last MR imaging session, mice were perfused intracardially with 0.1 M 
Phosphate-buffered saline and formalin. The heads were then dissected and fixed in formalin for 
24 hrs. The brains were removed from skulls and embedded in paraffin. The brain was coronally 
sectioned and 8-micron-thick tissue sections were stained with hematoxylin and eosin (H&E) 
according to standard protocols. For each brain, a single slice reflecting the same anatomic 
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features was chosen for comparison. 
Clonogenic survival assay 
Clonogenic survival assays were performed as described previously[156]. Briefly, calculated 
numbers of cells were plated to enable normalization for plating efficiencies. Cells were allowed 
to attach for 5 hours and then irradiated with 0, 2, 4, 6 or 8 Gy. After 7-10 days of incubation, 
plates were fixed with 70% ethanol and stained with 1% methylene blue. Colonies consisting 
of >50 cells were counted by viewing the plates under a microscope. The survival fractions were 
calculated as (number of colonies / number of cells plated) / (number of colonies for 
corresponding control / number of cells plated). 
Statistical analysis 
For experiment “A”, the weekly changes of necrotic volumes for each group were summarized 
using means and standard deviations. Because of the relatively large variability in these volumes, 
a logarithm transformation was performed to better satisfy the assumption of a normal 
distribution. Two-way ANOVA was used to compare the mean volumes of radiation necrosis 
among treatment groups, followed by ad hoc multiple comparisons for between-group 
differences at specific time points. For experiment “B”, “Last Observation Carried Forward 
(LOCF)” analysis was used for visualization of tumor growth. Two-way ANOVA was used to 
compare the mean tumor volumes among treatment groups, followed by ad hoc multiple 
comparisons for between-group differences at specific time points. All tests were two-sided and a 
p-value of 0.05 or less was taken to indicate statistical significance. The statistical analysis was 
performed using SAS 9.3 (SAS Institutes, Cary, NC). 
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Results 
MRI detects radiation necrosis as image hyperintensity in T1-weighted images 
Representative T1-weighted spin-echo images of SB 415286-treated and DMSO-treated mice, 
covering the same anatomic region of the brain and collected at 13, 16, 19, and 22 weeks 
following a single 45-Gy dose of radiation are shown in Figure 1. Hyperintense areas in these 
images correspond with regions of RN in the brain. Evident hyperintense regions are clearly seen 
in DMSO-treated, control mice at 13 weeks post-irradiation and these regions expand 
significantly in extent by 22 weeks. The images of SB 415286-treated mice (1mg/kg) show 
minimal hyperintensity, even at 22 weeks post-irradiation. 
Necrosis volumes can be measured quantitatively from MR images 
The development of RN is associated with hyperintensity in both T2-weighted and contrast-
enhanced, T1-weighted images. At each time point, regions of interest were drawn around the 
entire brain in several contiguous image slices, chosen to include the entire hyperintense region. 
Each brain was divided along the midline into left (irradiated) and right (non-irradiated) 
hemispheres. The image intensity for each individual pixel in the left hemisphere was normalized 
by the average of the 25 pixels (5 x 5 square) including and immediately surrounding its mirror-
image pixel in the right hemisphere, and histograms of normalized intensity for the irradiated 
hemisphere were constructed. We have performed this same analysis previously in a cohort 
(n=10) of non-irradiated mice and shown that the resulting histogram is symmetric; with 99% of 
the pixels being distributed in the intensity range 0.6 – 1.4 about a normalized mean of 1.0. 
Therefore, an intensity threshold of 1.4 was chosen as the cutoff for normal brain tissue. The 
number of pixels exceeding this threshold measures the necrotic volume at each time point for 
irradiated mice. 
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GSK-3β inhibitor slows the progression of radiation necrosis in brain tissue 
Figure 2A shows the progression of the volumes of MRI-derived necrotic regions for DMSO-
treated (red) and SB 415286-treated (blue) mice (1mg/kg), in which all the mice received a 
single, 45-Gy dose of radiation. Seven out of 12 mice treated with SB 415286 had smaller 
necrotic regions at 22 weeks compared with control mice. The neuroprotective effect is clearly 
evident in the progression of the mean volumes (Figure 2B), in which the treated cohort had a 
greatly diminished volume of necrosis at weeks 16, 19 and 22 post-irradiation compared to 
DMSO-treated controls (p=0.0024, 0.0003, and 0.0056 for weeks 16, 19 and 22, respectively). 
Histology reveals that GSK-3β inhibitor protects against radiation necrosis in irradiated 
brain tissue 
Figure 3 shows 2x (top) and 10x (middle) H&E histologic images and corresponding T1-
weighted MR images (bottom) for DMSO-treated, and SB 415286-treated mice (1mg/kg) at 22 
weeks following a single, 45 Gy dose of radiation. The irradiated hemispheres of the DMSO-
treated mice demonstrated many of the classic histologic features of RN, including fibrinoid 
vascular necrosis (black arrow), vascular telangiectasia (yellow arrows), hemorrhage (red arrow), 
and loss of neurons and edema (blue arrows) [4]. In contrast, the irradiated hemisphere of the SB 
415286-treated mouse showed only minimal tissue damage. These histologic findings support 
the MR data shown in Figure 2, demonstrating a significant neuroprotective effect of GSK-3β 
inhibition. 
GSK-3β inhibitor does not affect the therapeutic efficacy of radiation on tumor tissue 
Figure 4 shows representative T1-weighted, spin-echo images of non-irradiated, radiation only, 
and radiation plus SB 415286-treated (1mg/kg) tumor-bearing mice; images cover the same 
anatomic region of the brain and were obtained on PID 10 and 20. Hyperintense areas in these 
images correspond with regions of tumor in the brain. Evident hyperintensity is clearly seen in 
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all three mice at PID 10, but only in the non-irradiated mice did the hyperintense region grow 
significantly in extent between PID 10 and 20. This is seen clearly in the tumor growth curves 
for the three cohorts (Figure 5). Tumors in non-irradiated mice grew quickly compared to the 
irradiated mice, while no significant difference was observed between radiation-treated mice 
with and without pre-treatment with SB 415286 (1mg/kg), demonstrating that SB 415286 does 
not affect the therapeutic efficacy of radiation. 
Survival data are shown in Figure 6A for all cohorts. If SB 415286 fully protected tumor cells 
from radiation, the survival curves of cohorts 1 and 3 would be the same. Instead, treatment with 
radiation plus SB 415286 leads to a significant increase in median survival compared with non-
irradiated controls (P=0.0024), a survival increase that was statistically indistinguishable from 
radiation treatment alone (P=0.9974). This observation demonstrates that administering the 
GSK-3β inhibitor SB 415286 has no effect on this glioma model’s sensitivity to radiation. We 
further evaluated the effect of the GSK-3β inhibitor SB 415286 on irradiated DBT cells in a 
colony formation assay. As shown in Figure 6B, the DBT glioma cells treated with 25 µM SB 
415286 showed significantly decreased survival following irradiation. SB 415286 did not protect, 
but in fact radiosensitized, the DBT cells in culture. 
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Discussion 
SB 415286, a small molecule inhibitor of GSK-3β, provides significant protection from 
radiation-induced apoptosis in neuronal cells in culture [147, 150]. MRI monitoring of RN, in 
concert with GK irradiation, offers an attractive strategy for validating the in vivo 
neuroprotective effect of this GSK-3β inhibitor with laboratory animals. We have established a 
mouse model that consistently reproduces the histology of RN observed in patients. Herein, we 
demonstrate that exposure to SB 415286 reduces the progression of RN in the mouse. The onset 
and progression of RN in mouse brain were characterized by measuring the volume of 
hyperintense regions on contrast-enhanced T1-weighted images. Characterization with T2-
weighted images yielded essentially equivalent findings (data not shown). The greatly reduced 
progression of RN in SB 415286-treated mice measured longitudinally by in vivo MR imaging, 
and corresponding histologic findings, clearly demonstrate the efficacy of this GSK-3β inhibitor. 
In addition, tumor-bearing mice treated with SB 415286 prior to irradiation show no difference 
in median survival compared with untreated, irradiated mice, suggesting that SB 415286 did not 
reduce the therapeutic efficacy of radiation on tumor tissue. These findings are entirely 
consistent with a colony formation assay of DBT glioma cells in culture. 
The neuroprotective effect of SB 415286 is dependent on the radiation dosing scheme. Mice 
receiving a single, 60-Gy dose of radiation showed no significant difference in the progression of 
RN between control and treated cohorts was observed (data not shown). The radiation dose-
response relationship has been modeled as a sigmoid function [122]. The results of these studies 
suggest that 45-Gy of radiation may be near the middle of the sigmoid curve for this mouse 
model of radiation necrosis, where small shifts in the curve due to treatment with SB 415286 can 
99 
 
generate a significant protective effect. 
Findings of the present study motivate consideration of SB 415286 as a potential neuroprotectant. 
However, its half-life is shorter than 24 hours. Assuming the inhibitor acts by targeting the acute 
apoptosis of glial cells and endothelial cells, a process that lasts longer than 24 hours, continuous 
use of SB 415286 following irradiation might, therefore, increase its therapeutic efficacy. Studies 
to optimize dosing schemes are a logical next step. 
Conclusion 
The data in this study demonstrate that (i) SB 415286, a small molecule inhibitor of GSK-3β, 
confers significant neuroprotection in a mouse model of RN and (ii) SB 415286 does not reduce 
the therapeutic efficacy of radiation on the mouse DBT glioma model of glioblastoma. 
Extrapolating to the clinic, should SB 415286 or other GSK-3β inhibitors reduce/prevent the 
development of necrosis in normal CNS tissue following irradiation, the development of more 
aggressive/effective radiation paradigms would likely follow. 
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Figures 
 
 
Figure 4.1. Representative transaxial T1-weighted spin-echo images. DMSO-treated (top) 
and SB 415286- treated (1mg/kg, bottom) mice at (from left to right) 13, 16, 19, and 22 weeks 
following a single 45-Gy dose, at 50% isodose, of radiation. Slices were chosen to display the 
same anatomic region of the brain at two time points. 
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Figure 4.2. Time course plots of MRI-derived necrotic volumes in mice irradiated 
hemispherically with a single 45-Gy dose of GK radiation. (A) Individual subject data for 
DMSO-treated and SB 415286 (1mg/kg) treated mice. (B) Summary data mean ± standard error, 
n=13 and 12 for control and SB 415286-treated mice, respectively. 
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Figure 4.3. H&E-stained sections display characteristic histologic features of RN and 
demonstrate neuroprotection by SB 415286. Representative 2x (top) and 10x (middle) H&E 
histology slices chosen near the radiation isocenter, and corresponding contrast-enhanced T1W 
images (bottom) DMSO-treated and (two different) SB 415286 (1mg/kg) treated mice at 22 
weeks following 45-Gy fraction of radiation. The irradiated hemispheres of the control mice 
show many of the histologic features that are characteristic of RN, including fibrinoid vascular 
necrosis (black arrow), vascular telangiectasia (yellow arrows), hemorrhage (red arrow), loss of 
neurons and edema (blue arrows). In addition, the tissue injury observed on the histology slices 
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is highly correlated with the hyperintense regions on T1-weighted images. These features are 
largely lacking or are reduced in severity in the SB 415286 -treated mice. 
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Figure 4.4. Representative transaxial T1-weighted spin-echo images. Untreated, tumor-bearing 
(left), radiation-treated, tumor-bearing (middle) and combination of radiation with SB 415286 
(1mg/kg) treated, tumor bearing (right) mice at 10 and 20 (from top to bottom) days post-
implantation with DBT glioma cells. Slices are chosen to display the same anatomic region of 
the brain at two time points. 
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Figure 4.5. Time course of MRI-derived tumor volumes for mice implanted with DBT glioma 
cells.  Mean ± standard error, n = 10 each for untreated, radiation-treated, and combined 
radiation- and SB 415286-treated mice. 
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Figure 4.6. A. Survival of tumor bearing mice. Percent surviving fraction is presented for 
DMSO-treated mice (black line, N=10), radiation-treated mice (red line, N=9), and combined 
radiation and SB 415286-treated mice (blue line, N=9). Both treatment regimes significantly 
increased median survival over the untreated group. Survival curves for the two treatment groups 
were statistically indistinguishable. B. Survival of cultured DBT glioma cells. Cells were treated 
with DMSO (ο) or 25 µM of SB 415286 (•) for 16 h, irradiated with 0, 2, 4, 6 and 8 Gy and 
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plated for clonogenic survival assay. After 10 days, colonies were fixed, stained with 1% 
methylene blue, and counted. Shown are the percent surviving fractions for DMSO- or SB 
415286-treated DBT cells. 
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Chapter 5 Characterizing Radiation Necrosis using qBOLD 
 
5.1 Introduction 
Several factors, including spin-spin interactions, imperfect static magnetic field, and 
susceptibility inhomogeneities due to air-tissue boundary, contribute to FID signal decay. The 
contribution from spin-spin interactions, a random effect, can be easily separated from 
contributions from other time-independent factor. In 1990, paramagnetic deoxyhemoglobin in 
blood vessel was discovered as an important fixed factor resulting in observable FID signal 
decay, also known as blood oxygenation level-dependent (BOLD) contrast [157]. Hemoglobin 
(Hb or Hgb) is the iron-containing oxygen-transport metalloprotein in the red blood cells. It 
carries oxygen (oxyhemoglobin) from the respiratory organs to the rest of the body where it 
releases the oxygen (deoxyhemoglobin) used to burn nutrients to provide energy to power the 
functions of the organism, and collects the resultant carbon dioxide to bring it back to the 
respiratory organs. Oxyhemoglobin and water in the soft tissue are slightly diamagnetic with an 
absolute susceptibility of about -9 ppm, while deoxyhemoglobin is paramagnetic with an 
absolute susceptibility of about 0.15 ppm. These magnetic susceptibility inhomogenities distort 
the local magnetic field and cause the FID signal decay. The relative length scale of the 
inhomogeneity induced by blood vessel is a distance smaller than the imaging voxel dimensions 
but much larger than the atomic and molecular scales. In contrast, the scale of the macroscopic 
magnetic field inhomogeneities, arising from magnet imperfections, body-air interfaces, and 
large sinuses inside the body, describes distances larger than the imaging voxel dimensions.    
BOLD contrast directly links to the concentration of deoxyhemoglobin, which depends primarily 
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on the oxygen extraction fraction (OEF) and deoxygenated cerebral blood volume (dCBV). This 
allows BOLD contrast to be useful in understanding brain function as well as the physiology of 
various tumors [158-162]. Most BOLD studies have focused on the temporal changes in the MR 
signal during changes in brain activity, also known as functional MRI (fMRI). Absolute 
quantitation of the BOLD signal and its constitutive components -- dCBV and OEF -- is difficult. 
Currently, there is no clinically accepted MRI-based method for measuring OEF in vivo. The 
only clinically accepted OEF measurement relies on PET techniques [92]. However, the PET-
based methods are limited in human study and clinical practice due to their low spatial resolution 
and the requirement of radionuclides. 
Recently, a quantitative BOLD method, based on an MR signal model in the presence of blood 
vessel network, has been developed in our laboratory [163]. It has been validated on phantoms 
[93, 164] and applied to the normal human brain in the baseline state [94]. The resulting OEF 
map is homogeneous across the entire brain with a mean of about 40%, and the dCBV map 
indicates that gray matter has ~3 times higher dCBV than white matter [165]. These results are 
supported by other reports, providing important validation of this approach. 
Remarkable changes in cerebral blood flow and oxygen consumption are suggested in the region 
of radiation necrosis [42]. Consequently, qBOLD could be a promising biomarker for radiation 
necrosis and provide additional function information to differentiate necrosis from recurrent 
tumor. The purpose of this study is to evaluate the feasibility of this approach in characterizing 
radiation necrosis in mouse brain.  
5.2 Methodology 
5.2.1 qBOLD theory 
In qBOLD theory, the blood vessel network is modeled as a collection of uniformly distributed 
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and randomly oriented cylinders of infinite length. The magnetic susceptibility of each cylinder 
is determined by OEF and dCBV. The extravascular FID signal in the presence of magnetic field 
inhomogeneities [166] induced by the blood vessel network is described by equation: 
[ ]tRttfdCBVtFStS c 20 )/(exp)()( −⋅−⋅⋅= ,                                     
where zero time t corresponds to the position of RF excitation pluse; S0 is the proton density; F(t) 
represents the effect of macroscopic magnetic field inhomogeneities due to an imperfect magnet 
and air-tissue boundary; R2 represents the T2 relaxation rate constant, and the characteristic 
dephasing time, tc, is defined as: 
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where B0 is the external magnetic field strength; γ is gyromagnetic ratio; χ represents the 
susceptibility difference between deoxygenated blood and surrounding soft tissue; Ya is the 
blood oxygenation level of arterial blood, which is approximately 1 under normal condition; Hct 
is the blood hematocrit measured independently from the sample blood  (e.g., ~40% for human); 
0χ∆ = 0.264 ppm, which is the susceptibility difference between completely deoxygenated and 
completely oxygenated blood.  
For uniformly distributed and randomly oriented blood vessels, f(t) is given by: 
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Correspondingly, the signal can be written as: 
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Figure 5.1 shows the time course of the normalized signal S(t)/S0 in the extreme case where  
F(t)=1, indicating an ideal homogeneous magnetic field. When t/tc is large, the curve is linear 
with a slope proportional to the product of dCBV and OEF. If we extend the linear part, the 
extrapolated point at t/tc=0 is dCBV. However, in real experiments, the function F(t) also decays 
non-linearly and cannot be ignored. It is the major complication in the calculation of OEF and 
dCBV.  
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Figure 5.1. The signal, Eq. (5.6), as a function of t/tc (logarithmic scale). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
dCBV 
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5.2.2 MRI pulse sequence 
Since the accurate measurement of the initial non-linear part in the curve is the key to decouple 
OEF and dCBV, it was proposed to use the Gradient Echo Sampling of Spin Echo (GESSE) 
sequence where MR signal is sampled around a spin echo [166]. Compared with the gradient 
echo sampling starting from the center of the spin echo, this sampling was demonstrated to 
increase the accuracy of the estimate of the initial non-linear part, and result in a more accurate 
estimate of OEF and dCBV [166]. 
 
 
 
 
 
 
 
 
 
 
117 
 
 
Figure 5.2. Schematic diagram of the GESSE sequence. 
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5.2.3 Auto shimming 
As mentioned, an extremely homogeneous magnetic field is required to minimize the effect of 
F(t) term and extract OEF and dCBV from the signal decay. Active shimming is commonly used 
prior to any operation of the magnet to adjust the homogeneity of the scanner’s magnetic field 
using shim coils with adjustable current. Our Agilent/Varian scanners allow both manual and 
automatic shimming across the entire space or within a user-defined voxel. Compared with 
manual shimming, automatic shimming is more efficient and accurate. The principle of 
automatic shimming is based on the accurate measurement of a field-map, which spatially maps 
the actual magnetic field in each imaging voxel. It is well known that any magnetic field can be 
described as a summation of gradients in different directions. Accordingly, the scanner can adjust 
the current flowing through the shim coils to compensate the inhomogeneities (gradients) in the 
shimming volume.          
5.2.4 Numerical simulation 
The trade-off between temporal/spatial resolutions and signal-noise-ratio (SNR) is an important 
factor for the accurate estimate of OEF and dCBV. In order to identify the minimum SNR, a 
numerical simulation was performed. Assuming the magnetic field is perfectly homogeneous (F(t) 
= 1), the signal was calculated by the equation shown below: 
[ ] ),()/(exp)( 2 σµgaussiancsim noisetRttfdCBVtS +−⋅−=                            
The signal is then fitted by Eq. (5.7) but without the noise term, to generate dCBV, OEF and R2. 
SNR is defined by S(t=0) divided by the standard deviation of the Gaussian noise, and is 
sampled from 20 to 520 in steps of 10. The differences between preset and fitted values of dCBV, 
OEF and R2 were compared at different SNR levels.      
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5.2.5 Data processing 
Hanning filter  
It is well known that the Fourier Transform based MR images suffer from intervoxel signal 
leakage due to Gibbs ringing artifacts. The Gibbs phenomenon arises from the facts that 1) 
Fourier sums overshoot at a jump discontinuity, such as the edge of a single voxel, and 2) this 
overshoot does not decay as the frequency increases. Various methods have been reported to 
ameliorate this phenomenon, including the smoother method of Fourier series summation, 
sigma-approximation, and wavelet transform with Haar basis functions [167]. 
Here, we applied a Hanning filter, which corresponds to the following transformation of the 
signal (in 2D case), to reduce Gibbs ringing artifacts and improve SNR: 
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where S(i,j) represents the raw signal in the image domain at position (i,j). 
Correction for macroscopic magnetic field inhomogeneities 
As discussed, the decoupling of OEF and dCBV requires an accurate determination of the effect 
of macroscopic magnetic field inhomogeneities. In 2D MRI, the through-plane macroscopic 
magnetic field inhomogeneities result from a constant magnetic field gradient across the imaging 
voxel and their influence on the signal can be calculated using the sinc-function approach [166, 
168]. However the contribution of the in-plane magnetic field inhomogeneities is complicated by 
the intervoxel signal leakage resulting from Gibbs ringing artifacts [169]. Natural linewidth 
chemical shift imaging (NL-CSI) has been proposed to eliminate the contribution from 
macroscopic magnetic field inhomogeneities mathematically, however, additional data are 
required to generate a high resolution field map.      
Recently, a novel voxel spread function (VSF) method [170] has been developed that utilizes 
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both magnitude and phase of MR images, allowing quantitative calculation of magnetic field 
inhomogeneity effects. The following is a brief description of the VSF algorithm. 
In the presence of an inhomogeneous magnetic field b(r), the signals in k-space and image 
domain for a 3D qBOLD experiment can be written as follows: 
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where TE is the gradient-echo time, t is the time during GE acquisition, ρ is the ideal signal at 
TE without any magnetic field inhomogeneities, Gx, Gy and Gz are phase encoding (x and y) 
and read-out (z) gradients, and ϕ0 is the phase shift at TE = 0. 
In practice, assuming that i) the total signal is the summation of signals from n imaging voxels; ii) 
the magnetic field inhomogeneities within each voxel are described as resulting from a small 
background gradient; and iii) the proton density is homogeneous across each voxel, the b(r) and 
ϕ0 can be further expressed as: 
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Thus, the k-space signal can be written as: 
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By defining a voxel spread function (VSF), the signal in image domain can be simplified as:  
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By calculating mjmjmm gb ϕϕ ,,, 0 using the phase image, ρm can be mathematically solved. However, 
this approach involves inversion of large matrices and it is time-consuming. An approximation 
can be achieved by assuming that the signals from neighboring voxels behave similarly in the 
absence of magnetic field inhomogeneities, which can be expressed as: 
)0()()0()( mnnm STESTE ⋅=⋅ ρρ                                             
In this case, the expression of Sn(TE) reduces to: 
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Therefore, the “ideal” signal in the absence of macroscopic magnetic field inhomogeneities can 
be obtained simply by dividing the signal by the F-function calculated from the phase image.     
   
5.3 Results 
Numerical simulation optimizes the qBOLD imaging parameters 
As shown in the Figure 5.2, the accurate estimates of OEF and dCBV require SNR higher than 
400. In contrast, the fitted values of R2 and the product of OEF and dCBV are close to their true 
values if SNR is higher than 50.  
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Figure 5.3. Numerical simulation. (from top to bottom) the fitted dCBV vs SNR; the fitted OEF 
vs SNR; the fitted T2* vs SNR; the product of dCBV and OEF vs SNR. 
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In order to obtain qBOLD images with a high SNR (>400), the imaging parameters are chosen as 
follows: 
6 slices with slice thickness = 1 mm, TE of spin echo = 43 ms, TR = 2000 ms, 30 echoes, delta 
TE = 1.64 ms, spin echo is at the 10th echo, FOV = 15 x 15 mm2, data matrix = 32 x 32, two 
blocks with each block has 16 averages, and the total scan time = 32 mins. 
After applying a Hanning filter, the resulting images are shown in Figure 5.3, and the 
corresponding SNRs for 30 echoes of the 3rd slice with or without the Hanning filter are shown 
in Figure 5.4. The 10th echo image with and without applying the Hanning filter has SNRs of 
approximately 400 and 1100, respectively, which matches the SNR requirement suggested by the 
previous numerical simulation.  
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Figure 5.4. qBOLD images after applying the Hanning filter. The first row shows the spin echo 
images for six contiguous slices. The bottom 5 x 6 panel represents 30 echoes for the third slice 
(in red outline). 
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Figure 5.5. SNR for a single mouse brain slice vs echo number with and without applying the 
Hanning filter. 
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Auto shimming reduces the macroscopic magnetic field inhomogeneities 
 
The advantage of automatic shimming over manual shimming is shown in a phantom study with 
a tube of water. In this dissertation, all the MR images were collected with a larger uniform-
excitation transmit coil and a small, high sensitivity surface receive coil. One drawback of the 
use of surface coil is that the signal intensity drops sharply with increasing distance between coil 
and imaging voxel. This sensitivity profile is clearly evident in the axial gradient-echo image of a 
tube of water (Figure 5.5). In general, manual shimming improves the field homogeneity by 
slowing the FID signal decay. Accordingly, manual shimming favors the region of higher 
sensitivity that contributes more to the overall FID signal. In contrast, automatic shimming is 
based on the calculation of a field map, which is independent of the sensitivity of the receiving 
coil. The resulting fieldmaps after shimming show clear differences between the two shimming 
methods (Figure 5.6). 
The following qBOLD experiments in mouse/rat brains were all performed after automatic 
shimming. The Full Width at the Half-Height (FWHH) of the spectrum for a tissue volume of 6 x 
12 x 9 mm3 in mouse brain is approximately 20 Hz (about 0.1 ppm in 4.7 Tesla) after automatic 
shimming, which usually takes about 5 – 6 minutes. Since the field change induced by blood 
vessel network is on the order of 10 Hz, the remaining macroscopic magnetic field 
inhomogeneities after automatic shimming cannot be ignored in the qBOLD data processing. The 
fieldmaps (Figure 5.7) show clearly that only a small region in the center of brain exhibits 
homogeneous field, while the top and bottom of the brain suffer from severe magnetic field 
inhomogeneities. A shimming experiment performed in an ex vivo mouse brain immersed in 
water confirms that the troublesome macroscopic magnetic field inhomogeneities arise from the 
tissue-air boundary and primarily, the air-filled ear cavities. The FWHH of the spectrum for the 
128 
 
same volume used for the in vivo experiment is 7 Hz, and the field maps (Figure 5.7) show large 
regions of homogeneous magnetic field, indicating a significant improvement of magnetic field 
homogeneities due to the susceptibility match. 
Unfortunately, it is technically demanding to fill the ear cavities of a mouse brain with water or 
other medium invasively.            
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Figure 5.6. The axial gradient echo image of a water-filled tube. The image was collected with a 
surface (receiving) and volume (transmitting) coil pair. It is noted that the signal intensity drops 
significantly along the direction perpendicular to the surface coil (red line). 
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Figure 5.7. Fieldmaps of a water-filled tube after manual shimming (top) and automatic 
shimming (bottom). Images are displayed on a scale of [-30Hz, 30Hz]. 
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Figure 5.8. Fieldmaps of an in vivo mouse brain (top) and an ex vivo mouse brain (bottom) 
merging in water after automatic shimming. Images are displayed on a scale of [-20Hz, 20Hz]. 
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VSF method reduces signal loss due to macroscopic magnetic field inhomogeneities 
Figure 5.8 shows the 30th gradient-echo qBOLD images from five contiguous slices before and 
after correction for macroscopic magnetic field inhomogeneities. It is evident that the ‘visible’ 
brain regions extend significantly on the images after correction for macroscopic 
inhomogeneities using the Voxel Spread Function method.  
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Figure 5.9. Representitive 30th gradient-echo qBOLD images from five contiguous slices before 
(top) and after (bottom) correction for macroscopic inhomogeneities using the Voxel Spread 
Function method. 
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Resulting OEF and dCBV maps  
The fitted OEF and dCBV maps for an irradiated mouse brain at 4 weeks post irradiation, as well 
as the corresponding T1W post-Gd enhanced images, are shown in Figure 5.9. The necrotic 
regions indicated by the minor hyperintensity regions on the T1W images have high OEF values 
and low dCBV values, which are consistent with our hypothesis. However, OEF values of the 
undamaged brain tissue are approximately 10-20%, far lower than the OEF values of normal 
brain tissue (~40%) reported elsewhere [171-173]. dCBV values of the regions near the edge of 
the brain are extremely high (>20%), most likely due to imperfect corrections for macroscopic 
magnetic field inhomogeneities.  
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Figure 5.10. OEF (top), dCBV (middle) maps and corresponding T1-weighted images (bottom) 
for an irradiated mouse at 4 weeks following a single 50-Gy dose of radiation. OEF maps are 
displayed on a scale of [0%, 100%] and dCBV maps are displayed on a scale of [0%, 5%]. 
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5.4 Discussion 
Although the qBOLD method has been demonstrated to provide regional, in vivo absolute 
measurement of OEF and dCBV in human brain, it does not produce convincing results in the 
mouse brain. SNR and the effects of macroscopic magnetic field homogeneities are two major 
factors that determine the feasibility of the qBOLD method. As suggested by the numerical 
simulation, a minimum SNR of 400 is required to decouple OEF and dCBV. However, the 
simulation has its limitation due to the assumption of an ideal homogeneous magnetic field. The 
imperfect correction of macroscopic magnetic field inhomogeneities will highly undermine the 
accuracy of estimates of OEF and dCBV. Therefore, the required SNR in practice should be 
much higher than 400. Switching to high field may not help, because both BOLD contrast and 
the effect of macroscopic magnetic field inhomogeneites are proportional to the field strength. 
Performing qBOLD experiments in a larger brain, such as rat brain, is a plausible option that 
provides x2 SNR using the same data matrix used in our mouse study.  
Shimming and post-processing correction are two ways to reduce the effects of macroscopic 
magnetic field inhomogeneities. It has been suggested that the shimming of mouse brain can be 
improved by placing a half-moon shaped head cap filled with 2% agarose gel between the mouse 
head and surface coil [174]. However, no significant improvement was observed when this 
experiment was attempted (data not shown). Further, the air-filled ear cavities, the primary 
sources of the macroscopic magnetic field inhomogeneities, are difficult to overcome for in vivo 
mouse studies.  
The voxel spread function (VSF) method has been validated in a phantom study. In in vivo 
mouse brain studies, it helps to recover the long-TE GE signal near the mouse ears. However, the 
distorted OEF and dCBV maps suggest that the effects of macroscopic inhomogeneities were not 
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completely eliminated. As mentioned, an accurate field map is needed in the calculation of the 
VSF function. In our experiments, the field map was calculated from the phase information of 
low-resolution qBOLD data. Measuring a high-resolution field map from another independent 
scan may improve the performance of the VSF method. 
Macroscopic magnetic field inhomogeneities can be considered to be static if the sample does 
not move. It may be possible to decouple these static effects from the deoxyhemoglobin-induced 
effects by changing blood flow in the mouse brain. For example, carbon dioxide leads to 
increased blood flow, resulting in enhanced oxyhemoglobin concentration and then increased 
MR signal. The effects of macroscopic inhomogeneities can then be eliminated by calculating 
the ratio of MR signals generated with two different breathing gases (100% oxygen vs. 95% 
oxygen + 5% carbon dioxide). However, new concerns arise, including smaller contrast, other 
factors affecting cerebral blood flow (e.g., breathing rates, heartbeat), and increased scan time 
(x2 at least).  
Independent verification of blood oxygen level must be included in future studies. The OEF 
values in normal brain tissue have been hypothesized to have a homogeneous distribution with a 
mean value of 40%. But the blood oxygen levels fluctuate among animals and vary from time to 
time. An independent in vivo measurement of blood oxygen levels at specific sites in the brain 
can help validate the qBOLD method in rodents.  
5.5 Conclusion 
A high SNR (400 at least) is required to decouple OEF and dCBV. The VSF function reduces the 
effect of macroscopic magnetic field inhomogeneities. With current shimming methods, imaging 
parameters, and post-process algorithms, the resulting OEF and dCBV maps in the mouse brain 
generated by qBOLD method are still not reliable. Efforts to boost the SNR, improve the 
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shimming and eliminate the effects of macroscopic magnetic field inhomogeneities are ongoing. 
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Chapter 6 Summary and Future Research 
 
6.1 Summary 
In this thesis work, we have developed a novel murine model of late time-to-onset radiation 
necrosis by employing the Leksell Gamma Knife Perfexion to stereotactically deliver radiation to 
one hemisphere of the mouse brain. This animal model can be used to reproducibly study 
radiation necrosis that simulates changes noted in the brains of human patients with radiation 
necrosis. A four-level histologic scoring system was developed to grade the severity of radiation 
necrosis. The onset and progression of RN in this model can be quantitatively characterized by 
both preclinical MRI and histology.  
The efficacies of SB 415286, an inhibitor of glycogen synthase kinase 3β (GSK-3β), as a 
neuroprotectant, and bevacizumab (Avastin) and B20-4.1.1, both vascular endothelial growth 
factor (VEGF) inhibitors, as mitigators of radiation necrosis in mice have been determined. B20-
4.1.1 significantly reduces the progression of RN in the mouse brain following a single 50-Gy 
dose of radiation, while bevacizumab shows only a temporal mitigative effect during the early 
stage of RN. When given prior to irradiation, SB 415286 also slows the progression of RN and 
does not reduce the therapeutic efficacy of radiation on tumors.  
The possibility of utilizing qBOLD method to quantify the hemodynamic parameters in mouse 
brain, including OEF and dCBV, has been discussed. Although qBOLD has been validated in 
phantom and human studies, a combination of the significantly decreased SNR and severe 
macroscopic magnetic field inhomogeneites, mainly resulting from air-filled ear cavities, 
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complicates the application of qBOLD in the mouse brain. With current shimming methods, scan 
parameters, and post-process algorithms, the decoupling of OEF and dCBV in the mouse brain 
using the qBOLD method is not reliable.  
6.2 Future research 
Optimize the dosing schedule of B20-4.1.1 in the treatment of RN 
Outstanding questions also remain regarding the ideal dosing schemes and the treatment periods 
for anti-VEGF-Ab therapy. Multiple dosing schemes, ranging from 5 mg/kg to 10 mg/kg have 
been reported in the treatments of tumor and radiation necrosis in both human and animal studies. 
Typically, bevacizumab, with a half-life of approximately 20 days in humans, is administered 
once every 2 or 3 weeks in patients, and once or twice weekly in mice. For our mitigation study, 
a high-end dosing scheme (10 mg/kg, twice weekly) was chosen and demonstrated promising 
mitigative effects on radiation necrosis in mice. Nonetheless, minimizing the dose required to 
effective control the progression of necrosis will reduce patient costs and potential side effects, 
thereby improving the likelihood of effective clinical translation. Studies measuring the effects of 
using lower doses of B20-4.1.1 in our mouse model are ongoing in our lab. Also, in the current 
studies, irradiated mice were treated with bevacizumab or B20-4.1.1 for 7 or 8 weeks, beginning 
with the first radiographic sign of radiation necrosis. However, the mitigative effectiveness found 
upon initiating the treatment earlier (e.g., immediately following irradiation) or stopping the 
treatment after a fixed period of time (e.g., 4 weeks) remain to be investigated. 
Verify the mechanism of anti-VEGF antibody in the treatment of RN 
The DCE experiments verified that the anti-VEGF therapy decreases the vascular permeability in 
the necrotic region; however, the role of BBB breakdown in the development of RN is still not 
fully understood. One hypothesis explaining the action of anti-VEGF therapy claims that the 
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acute BBB breakdown leads to a change in the surrounding micro environment and consequently, 
the onset of radiation necrosis [16]. However, we did not observe any acute injury (e.g., 
immediately following the irradiation and up to 4 weeks) in this Gamma Knife mouse model of 
radiation necrosis, by either DCE measurement or Evans Blue stain [175]. As the development of 
RN has been suggested to be a continuous process [16] and biological changes are expected 
immediately following the high-dose irradiation, DCE MR imaging and Evans Blue stain may 
not have sufficient sensitivity to detect the cellular response. Therefore, future studies that 
address mechanism of action need include other cellular biomarkers.  
Determine the efficacy of other commercialized GSK-3β inhibitors as neuroprotectant 
Our results demonstrate the significant neuroprotective effect of SB 415286. However, SB 
415286 is no longer being pursued clinically by Glaxo SmithKline because of toxicity concerns. 
Future neuroprotection studies will utilize other GSK-3β inhibitors, such as lithium and valproic 
acid.     
Improve qBOLD in the brain of small animal 
1). Performing qBOLD experiments in a larger brain, such as rat brain, is an alternative 
providing x2 SNR with the same data matrix used in the current mouse study. Also, a larger brain 
enables the selection of tissue far away from the anatomic features which cause severe magnetic 
field inhomogeneities.  
2). An independent measurement of the high-resolution field map may improve the accuracy of 
the VSF method and lead to a better correction of magnetic field inhomogeneities.  
3). Changing blood flow in the mouse brain may enable decoupling of the macroscopic magnetic 
field inhomogeneities, which are static if the sample does not move, from the deoxyhemoglobin-
induced effects. A practical way is to switch the composition of breathing gase (e.g., 100% 
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oxygen vs. 95% oxygen + 5% carbon dioxide). Carbon dioxide leads to increased blood flow, 
resulting in enhanced oxyhemoglobin concentration and increased MR signal. The effects of 
macroscopic inhomogeneities can then be eliminated by calculating the ratio of MR signals 
generated with these two different breathing gases.  
4). OEF values in the normal brain tissue have been hypothesized to have a homogeneous 
distribution with a mean value of 40%. But the blood oxygen levels fluctuate among animals and 
vary from time to time. An independent in vivo measurement of blood oxygen levels at specific 
sites in the brain can help validate the qBOLD method.  
Develop an animal model of tumor and necrosis 
Developing methods at the pre-clinical level to differentiate recurrent tumor and radiation 
necrosis requires the development of a mixed animal model of tumor and necrosis. The major 
difficulties are i) to coordinate the progression timelines of tumor and necrosis; ii) to accurately 
irradiate a portion of tumor in order to produce a mixture of tumor and necrosis. A recent paper 
described a model of radiation necrosis in rats bearing human glioblastoma (GBM) in a small 
group of rats (n=3) [102]. A treatment plan was generated using a 4 mm radiosurgery cone such 
that one portion of the tumor received 100% dose of 60-Gy sufficient to cause necrosis, whereas 
the tumor edge at depth received only 50% or less dose, allowing for regrowth of the tumor. 
Future studies need direct efforts toward developing a mouse model of RN in tumor-bearing 
animals.  
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